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IDENTITY: SEQUENCE I 
100.0' CGPCFTTDEQHEQKCAECCGG--IGKCYGPQCLCNR (SEQIDHO:l) 
97.1% CGPCFTTDHQTEQICAECCGG--IGKCYGP~CNR (SEQIDN012C) 
94.1% CGPCFTTDBQTEQKCAECCGG--IGKCYGPQCLC-R (SEQION0121) 
94.U CGPCFTTDRQMEQKCAECCGG--IGKCYGPQCLC-R (SEQIDN0122i 
82.4' CGPCF'l'TDANHARKCiECCGG--IGKCPGPQCLCNRI (SEQ ID N0123) 
79.U CGPCFTTDANMARKCRECCGG--NGKCFGPQCLCNRE (SEQ ID N0:24) 
79.4' CGPCFTTDPYTESICATCCGG--RGKCVGPQCLCNRI (SEQ ID N0:25) 
76.5% CGPCFTKDPE'lEKKCATCCGG--IGRCFGPQCLCNRGY (SEQ ID N0126) 
76.St MCMPCmDBNMAKKCRDCCGG--NGXCFGPQCLCNR (SEQ ID ND:27) 
75.0t MCMPCHTDBQMARKCDDCCGGKGRGXCYGPQCLC-R (SEQ ID ND:2B) 
75.0% KCMPCFTrDBQMARKCDDCCGGXGRGXCYGPQCLC-R (SEQ ID N0:29) 
75.0\ RCJ:PCrrTDPQMSKKCADCCGGKGKGKCYGPQCLC- (SEQ ID N013D) 
73.5% MCMPCFTTDPNMAXKCRDCCGG-·NGKCl'GPQCLCNR (SEQ ID N0:31) 
70.6% MCMPCFTTDPNMANKcmx:GG--GKKCl'GPQCLCNR (SEQ ID N0:32) 
6B.B% JtCSPCF'l"l'DQQMTKKCYDCCGGKGXGKCYGPQCIC--APY (SEQ ID N0:33) 
65.6' MCMPCFTTRPD~C!G--RGKCPGPQCLC--GYD (SEQ ID N0:34) 
65.6' JtCGPCFTTDPQTQAKCSECCGRK-GGVCKGPQCLC--GIQ (SEQ ID N0:35) 
62.5% KCMPCF'l'TDBQTARRCRDCCGGR-GRXCFG-QCLC--GYD (SEQ ID N0:36) 
56.2% RCPPCTTTNPNMEADCRXCCGG··RGYCASYQCIC--PGG (SEQ ID ND:37) 
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100.0% CGPCFTTDHQMEQKCAECCGG--IGKCYGPQCLCNR (SEQ ID NO:l) 
97 .1% CGPCFTTDHQTEQKCAECCGG--IGKCYGPQCLCNR (SEQ ID N0:20) 
94.1% CGPCFTTDHQTEQKCAECCGG--IGKCYGPQCLC-R (SEQ ID N0:21) 
94.1% CGPCFTTDRQMEQKCAECCGG--IGKCYGPQCLC-R (SEQ ID N0:22) 
82.4% CGPCFTTDANMARKCRECCGG--IGKCFGPQCLCNRI (SEQ ID N0:23) 
79.4% CGPCFTTDANMARKCRECCGG--NGKCFGPQCLCNRE (SEQ ID N0:24) 
79.4% CGPCFTTDPYTESKCATCCGG--RGKCVGPQCLCNRI (SEQ ID N0:25) 
76.5% CGPCFTKDPETEKKCATCCGG--IGRCFGPQCLCNRGY (SEQ ID N0:26) 
7 6. 5 % MCMPCFTTDHNMAKKCRDCCGG--NGKCFGPQCLCNR (SEQ ID NO: 2 7) 
75.0% MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLC-R (SEQ ID N0:28) 
75.0% MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLC-R (SEQ ID N0:29) 
75.0% RCKPCFTTDPQMSKKCADCCGGKGKGKCYGPQCLC- (SEQ ID N0:30) 
73.5% MCMPCFTTDPNMAKKCRDCCGG--NGKCFGPQCLCNR (SEQ ID N0:31) 
70.6% MCMPCFTTDPNMANKCRDCCGG--GKKCFGPQCLCNR (SEQ ID N0:32) 
58.8% RCSPCFTTDQQMTKKCYDCCGGKGKGKCYGPQCIC--APY (SEQ ID N0:33) 
55. 6% MCMPCFTTRPDMAQQCRACCKG--RGKCFGPQCLC--GYD (SEQ ID NO: 34) 
55, 6% RCGPCFTTDPQTQAKCSECCGRK-GGVCKGPQCLC--GIQ (SEQ ID NO: 35) 
62, 5 % MCMPCFTTDHQTARRCRDCCGGR-GRKCFG-QCLC --GYD (SEQ ID NO: 36) 
56.2% RCPPCFTTNPNMEADCRKCCGG--RGYCASYQCIC--PGG (SEQ ID N0:37) 
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ABC TRANSPORTER LIGAND GATXl 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a filing under 35 U.S.C. §371 of PCT/ 
US2007 /069243 filed with the U.S. Receiving Office of the 
Patent Cooperation Treaty on May 18, 2007, and claims pri-
ority to and benefit of U.S. Provisional Application No. 
60/801,863 filed on May 19, 2006 by Nae! McCarty, Matthew 
Fuller, and Julia Kubanek, and where permissible is incorpo-
rated herein in its entirety. 
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awarded to Nae! McCarty by the National Science Founda-
tion; and Grant No. MCCART06PO awarded to Nae! 
McCarty by the Cystic Fibrosis Foundation. Therefore, the 
US government has certain rights in the claimed subject mat-
ter. 
FIELD OF THE INVENTION 
2 
lagged far behind that of their cation-permeable peers. One 
clear reason for this discrepancy is a paucity of specific 
probes that may be useful as tools for studying the permeation 
pathways and/or gating mechanisms, of Cl- channels. Indeed, 
5 the c1- channel blockers available at present work with very 
low affinity and poor specificity. 
Venoms from snakes, scorpions, marine snails, and spiders 
are rich sources of peptide ligands that have proven to be of 
great value in the functional exploration of cation channels . 
10 Peptide ligands have proven to be among the most potent and 
selective antagonists available for voltage-gated channels 
permeable to K+, Na+, and Ca2 +, and have been very useful 
tools for detailed structural analysis of these proteins. Pore-
blocking toxins provide clues about the arrangement of chan-
15 nel domains, about the interactions between the permeant 
ions and the pore, and about the proximity and interactions of 
the gating machinery with the pore. Gating modifiers provide 
tools to dissect the processes underlying the transitions 
between gating states. Peptide ligands have high potential as 
20 lead compounds for the development of therapeutics target-
ing pain, diabetes, multiple sclerosis, cardiovascular dis-
eases, and cancer. Because peptide ligands have well-defined 
structures, constrained by disulfide bridges, they bind with 
much higher affinity and specificity than other blockers avail-
25 able to date, and report the structures of their targets at 
molecular detail. Unfortunately, although several potential 
chloride channel toxins have been identified, peptide inhibi-
tors of chloride channels of an identified molecular target, 
including CFTR, have not been described. 
Aspects of the invention are generally related to ligands for 
ABC transporters, for example peptide ligands isolated from 
scorpion venom, pharmaceutical compositions thereof, and 30 
methods of use. 
In 1992, Strichartz and colleagues described the isolation 
of chlorotoxin (C!Tx), a small basic peptide capable of inhib-
iting low-conductance c1- channels from rat colon or brain 
reconstituted into lipid bilayers. However, neither recombi-
nant C!Tx, nor native C!Tx isolated from venom, has been 
BACKGROUND OF THE INVENTION 
The ATP-binding cassette (ABC) transporter superfamiiy 35 shown to block CFTR or any other c1- channel of known 
contains membrane proteins that translocate a wide variety of molecular identity. Native C!Tx also had no effect on Ca2 +-
substrates across extra- and intracellular membranes, includ- activated c1- channels or volume-regulated c1- channels, 
ing metabolic products, lipids and sterols, and drugs. Over- when applied to the bath. Sontheimer and colleages have 
expression of certain ABC transporters occurs in cancer cell shown that C!Tx inhibits the migration of glioma cells by 
lines and tumors that are multidrugresistant Genetic variation 40 inhibition of matrix metalloproteinase-2. A recent study sug-
in. these genes is the cause or contributor to a wide variety of gests that recombinant C!Tx inhibits an endogenous Ca2 + -
human disorders with Mendelian and complex inheritance activated c1- channel in astrocytes, but the molecular identity 
including cystic fibrosis, neurological disease, retinal degen- of this channel is also unknown. 
eration, cholesterol and bile transport defects, anemia, and Structure/function studies have led to improved under-
drug response phenotypes. Comparison of the human ABC 45 standing of which parts of the CFTR protein form the perme-
superfamily to that of other sequenced eukaryotes including ation pathway, and of the mechanism of binding andhydroly-
Drosophila indicated that there is a rapid rate of birth and sis of ATP at the NBDs that regulate channel gating. However, 
death of ABC genes and that most members carry out highly little is known about how binding and hydrolysis of ATP 
specific functions that are not conserved across distantly controls the conformation of the pore to regulate transitions 
related phyla. 50 between open and closed states. The availability of a peptide 
The ABC transporter family includes cystic fibrosis trans- that interacts with CFTR in a state-dependent manner will 
membrane conductance regulator (CFTR). CFTR functions allow the application of quantitative approaches previously 
as transporter or channel for chloride ions. Chloride is the not accessible for answering these questions. 
predominant physiological anion; therefore, c1- channels Therefore, it is an object to provide ABC transporter 
play critical roles in cell physiology. Plasma membrane c1- 55 ligands and methods of their use. 
channels are crucial to the process of secretion in many epi- It is another object to provide peptide compositions that 
thelial tissues such as the kidney, the intestine, and the airway. interact with CFTR in a state-dependent manner. 
Plasma membrane c1- channels are involved in cell volume It is another object to provide peptide compositions that 
regulation in a wide variety of cells. Intracellular c1- channels 
play important roles as anion shunt pathways for endosomal 60 
acidification. A c1- channel gene is the locus of the primary 
defect in several human diseases; including Bartter's syn-
drome, Dent's disease, myotonia, and some forms of epi-
lepsy; c1- channel proteins play important roles in a variety of 
other conditions, including cancer. Despite their central roles 65 
in many physiological processes, our understanding of the 
structures and mechanisms of anion-permeable channels has 
block or inhibit c1- channels. 
It is yet anotherobject to provide peptide compositions that 
block or inhibit c1- channels for the manufacture of a medi-
cament. 
It is another object to provide pharmaceutical peptide ion 
channel blockers or inhibitors and methods of use thereof. 
It is still another object to provide methods for treating 
ABC transporter-related disorders with peptide inhibitors of 
ion channels. 
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SUMMARY OF THE INVENTION 
Compositions and methods of using ABC transporter 
ligands are provided. In one aspect, the ABC transporter 
ligand is a scorpion venom peptide having at least 80% 5 
sequence identity to CGPCFTTDHQMEQKCAECCG-
GIGKCYGPQCLCNR (SEQ ID NO:l) (also referred to as 
GaTxl ). Variants and derivatives of the peptide ligand are also 
provided. The peptide ligand is believed to have a molecular 
mass of about 3.7 kDa and interacts with the cystic fibrosis 10 
transmembrane conductance regulator. The peptide ligand 
interacts with cystic fibrosis transmembrane conductance 
regulator in the interburst state, and reversibly binds to the 
CFTR when the CFTR is in the closed state. Binding of the 
peptide to the CFTR locks the chloride channel in the closed 15 
state. 
Expanded WT-CFTR bursts in the absence and presence of 
Lqh venom fraction C. Note that fraction C also introduces 
intraburst closures that are not observed in the absence of the 
fraction. Thus, Lqh venom fraction C fully recapitulates the 
activity ofLqh-pfvenom. 
FIG. 3: Fractionation of venom by size exclusion chroma-
tography. (a) Representative chromatogram of fraction C 
applied to a size exclusion colunm. Fractions were collected 
every 10 minutes and pooled into 30 minute fractions. The 
dashed line indicates baseline absorbance of elution buffer. 
Solid brackets indicate elution times for the indicated 
molecular weight standards in calibration runs ( dextrans, 2 
million Da; cytochrome C, 12,384 Da; vitamin B, 1,255 Da). 
(b) Representative single channel recording in the absence 
and presence of venom fraction C-gf30-32. (c) Expanded 
single channel burst ofWT-CFTR in the presence of the active 
In another aspect, the peptide ligand is isolated from Leiu-
rus quinquestriatus hebraeus venom. 
Another aspect provides a nucleic acid encoding a 
polypeptide having at least 80% sequence identity to SEQ ID 
NO:l. 
Still another aspect provides a method for reducing ABC 
transporter activity by contacting the ABC transporter with 
the disclosed ABC transporter ligands. 
Still another aspect provides a method of reducing chloride 
transport through a chloride charmel by contacting the chlo-
ride channel with the polypeptide ligand. 
Yet another aspect provides a method fortreating a disorder 
or symptom of a disorder related to aberrant chloride channel 
activity by administering a therapeutically effective amount 
of the polypeptide ligand. The disorder can be selected from 
the group consisting of cancer, cystic fibrosis, epilepsy, renal 
tubular disorders, Bartter's syndrome, Dent's disease, myo-
tonia, osteopetrosis, Angleman or Prader-Willi, upregulation 
of chloride channels in glioma cells, diarrhea-predominant 
inflammatory bowel syndrome, autosomal dominant poly-
cystic kidney disease (ADPKD), and secretory diarrhea 
Another aspect provides an antibody specific for the dis-
closed peptide ligands. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1: Scorpion venom inhibits CFTR in a complex man-
ner, (a) Domain architecture ofWT-CFTR and Flag-cut-llR-
CFTR. (b) Representative macropatch traces of WT-CFTR 
(left) and Flag-cut-llR-CFTR (right) in the absence and pres-
ence of 0.1 mg/mL equivalent Lqh-pf venom. Venom was 
applied 30 seconds prior to second exposure to 1 mM MgATP. 
( c) Representative single channel recording of WT-CFTR 
with and without 0.1 mg/mL Lqh-pf venom, showing 
increased interburst closed time. ( d) Expanded single channel 
trace of a WT-CFTR burst in the absence and presence of 
Lqh-pf venom showing the introduction of venom-induced 
intraburst closed states. 
FIG. 2: inhibitionofCFTR byLqh-pfvenomfractionC. (a) 
Representative RP-HPLC chromatogram of Lqh-pf venom. 
Fractions A-E of the eluate were collected during successive 
ten minute intervals, (b) Summary data of average percent 
inhibition ofWT- or Flag-cut-llR-CFTR macropatch currents 
by venom fractions at 0.1 or 0.3 mg/mL equivalent, respec-
tively. Error bars show mean±S.E. for n=3-4 observations at 
each condition. Fraction C showed the highest activity. ( c) 
Representative macropatch currents of WT- and Flag-cut-
llR-CFTR in die absence or presence of Lqh venom fraction 
C. ( d) Representative single charmel traces of WT-CFTR in 
the absence and presence ofLqh venom fraction C. Fraction 
C inhibits WT-CFTR by inducing long interburst closures. ( e) 
fraction showing that the component of venom causing 
intraburst inhibition is no longer present. 
FIG. 4: Isolation of the active peak, (a) Representative 
20 RP-HPLC chromatogram of fraction C-gf30-32. Individual 
peaks were collected and tested for activity as in FIG. 1. The 
arrow indicates the active peak, peak #6. (b) Representative 
single channel trace in the absence and presence of peak #6. 
The isolated toxin Inhibits CFTR by increasing the interburst 
25 closed duration. ( c) Expanded section of trace showing that 
peak #6 does not induce intraburst inhibition. 
FIG. 5: Proteomic characterizationofGaTxl. (a) MALDI-
MS spectrum of peak #6, showing a prominent mass of -3.7 
kDa. (b) Alignment of the GaTxl sequence with other scor-
30 pion toxins shows that GaTxl is a novel peptide. (c) Com-
parison of the C!Tx NMR structure (left) and the GaTxl 
homology model (right), in three orientations. Disulfide 
bridges are shown in the upper panels. (d) Sequence align-
ment of GaTxl (SEQ ID NO: 1) with the sequences of chlo-
35 rotoxin (C!Tx) (SEQ ID N0:29) and charybdotoxin (ChTx) 
(SEQ ID N0:39). Predicted secondary structure is indicated 
above the sequences while disulfide bridge linkage between 
conserved cysteines is indicated below. The dashed line indi-
40 
cates the disulfide bridge absent in ChTx. 
FIG. 6: Native GaTxl inhibits CFTR by increasing the 
interburst closed duration. (a) Representative single channel 
traces of WT-CFTR in the absence and presence of 0.1 
mg/mL venom equivalent GaTxl; this dilution was deter-
mined by amino acid analysis to provide 60 nM native 
45 GaTxl. Open probability was significantly reduced in the 
presence of toxin, (b-e) Burst analysis of CFTR open dura-
tions in the absence (b) and presence (c) ofGaTxl, and CFTR 
closed durations in the absence ( d) and presence ( e) of 
GaTxl. For this analysis, the record after toxin washout was 
50 used as control, to account for any potential, loss of channel 
activity due to rundown. Toxin increased the interburst closed 
time, but had no significant effect on CFTR open duration. 
The closed duration histogram in the presence of toxin was fit 
best with the sum of two exponential functions with time-
55 constants i:1=5316.3 ms (fractional amplitude=19.8%) and 
i:2 =74.1 ms (fractional amplitude=80.2%). 
FIG. 7: Synthetic GaTxl inhibits CFTR with high affinity. 
(a) Representative multi-channel trace ofFlag-cut-llR-CFTR 
in the absence and presence of250 nM synthetic GaTxl, with 
60 continual exposure to 0.2 mM ATP. (b) Dose-response curve 
calculated from window currents measured at 5, 20, 50, and 
250 nM synthetic GaTxl. Each filled symbol and error bar 
represents calculation of window current from a single patch 
at that concentration where macroscopic current was calcu-
65 lated within five randomly-chosen 3-minute segments each 
under control and experimental conditions. The open circle 
represents apparent inhibition calculated from sequential 
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exposures to solution containing 0.2 mMATP without toxin, 
as negative control; these data are not significantly different 
from zero. The dose-response curve was fit with a 3-param-
eter Hill function giving KD=24.9 nM, Vmax=71.5% inhibi-
tion, and Hill coefficient=l.95 (correlation coefficient 5 
r2=0.998). Filled triangle shows data from an experiment 
with 50 nM GaTxl in presence of 1 mM ATP. 
FIG. 8: MALDI-MS spectra of synthetic forms-ofGaTxl. 
(a) GaTxl was synthesized as described in Methods and 
subjected to MALDI-MS. Prior to cyclization, the linear pep- 10 
tide showed a mass of3,682.1 Da, and also displayed a doubly 
charged state at m/z=l,842.5. (b) MALDI-MS of crude 
cyclized GaTxl showed a major component at m/z=3,674.2, 
as well as a doubly charged state at m/z=l,838.6. (c) After 
RP-HPLC purification of the dominant component of the 15 
cyclized peptide, themajor-peakexhibitedm/z=3,674.1, with 
the doubly charged state still present. The decrease in mass by 
8 a.m.u. upon cyclization is consistent with the presence of 8 
cysteine residues that participate in 4 disulfide bridges. 
FIG. 9: Comparison of RP-HPLC of native and synthetic 20 
GaTxl. RP-HPLC of intracellular recording solution ((a) as 
blank), native GaTxl (b), and synthetic GaTxl(c) was per-
formed using a Zorbax 300SB-C3 colunm. For native toxin, 
three significant components eluted from the colunm; how-
ever, the peak with a retention time of13 minutes exhibited no 25 
absorbance at 280 nM (not shown) and thus is unlikely to be 
a protein. The two remaining peaks may reflect two different 
conformations of the same peptide, since the sequencing data 
suggested the presence of only one molecular species. Fol-
lowing purification by preparative HPLC (not shown), the 30 
major folding product of synthetic GaTxl eluted at a reten-
tion time identical to that of one of the major peaks for native 
toxin (indicated by the arrow in part (b) ). 
FIG. 10: GaTxl does not inhibit CIC voltage-gated chlo-
ride channels or Shaker Kvl .1 K+ charmels. The effect of 60 35 
nM synthetic GaTxl on CIC-1 (a) and CIC-2 (b). or 25 nM 
GaTxl on ShB-IR (c) was determined using two-electrode 
voltage-clamp. The top panels in (a) and (b) show currents 
measured in response to a range of step potentials as previ-
ously described 30. For CIC-1, membrane potential was held 40 
at -30 m V, and stepped to potentials ranging from -160 to 
+60 m Vin 20 m V steps of 160 ms duration, with a tail pulse 
at -120 mV for 40 ms. For CIC-2, membrane potential was 
held at -30 mV, and then stepped to potentials ranging from 
-160 to +60 m Vin 20 m V steps, with a pulse duration, of3 s, 45 
and a tail pulse at +40 m V for 500 ms (upper panel) or 100 ms 
(lower panel). The lower panels show only currents from the 
most depolarizing pulse for CIC-1 ( +60 m V) and the most 
hyperpolarizing pulse for CIC-2 (-160 m V), in the absence 
and presence of 60 nM GaTxl (solid and thin dashed lines, 50 
respectively). For ShB-IR, holding potential was -90 mV. 
Leak subtraction used a P/4 protocol with a conditioning 
pulse to -120 mV. Voltage was stepped from -100 mV post-
train to potentials ranging from -40 to 0 m V in 10 m V 
increments. The lower panel in part (C) shows only currents 55 
from the most depolarizing pulse (0 m V), in the absence and 
presence of 25 nM GaTxl (solid and overlying thin dashed, 
lines, respectively), at left, and similar data in the absence and 
presence of24 nM ChTx, at right. The gray trace in the record 
at right shows washout of ChTx, (d) Fractional CIC-1 or 60 
CIC-2 current remaining in the presence of GaTxl at the 
indicated potentials. ( e) Fractional ShB-IR current remaining 
in the presence of GaTxl for either peak current or current at 
the end of the voltage pulse. Scale bars in (a) represent 2 µA 
and 20 ms. Scale bars in (b) represent 1 µA and 500 ms (top) 65 
or 200 ms (bottom). Scale bars in ( c) represent 2 µA and 100 
ms. 
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DETAILED DESCRIPTION OF THE INVENTION 
I. Definitions 
The term "ABC transporter ligand" refers to a molecule or 
compound that interacts with an ABC transporter. An exem-
plary ABC transporter ligand include a polypeptide having at 
least 80% sequence identity to SEQ ID NO: 1. The terms 
"scorpion venom polypeptide", "peptide toxin", "GaTxl", 
and "ABC transporter ligand" arc used interchangeably. 
The term "antibody" includes complete antibodies, as well 
as fragments thereof (e.g. F(ab')2 , Fab, etc.) and modified 
antibodies produced therefrom (e.g., antibodies modified 
through chemical, biochemical, or recombinant DNA meth-
odologies), with the proviso that the antibody fragments and 
modified antibodies retain antigen binding characteristics 
sufficiently similar to the starting antibody so as to provide for 
specific detection of antigen. 
By "antisense polynucleotide" is meant a polynucleotide 
having a nucleotide sequence complementary to a given poly-
nucleotide sequence including polynucleotide sequences 
associated with the transcription or translation of the given 
polynucleotide sequence (e.g., a promoter), where the anti-
sense polynucleotide is capable of hybridizing to a polynucle-
otide sequence. Of particular interest are antisense polynucle-
otides capable of inhibiting transcription and/or translation, 
either in vitro or in vivo. 
By "antivenom" is meant an antivenin or an antitoxin to a 
venom; or an antiserum, containing such antitoxin. 
The term "biologically active" refers to ABC transporter 
ligands having structural, regulatory, or biochemical func-
tions of a naturally occurring polypeptide. Likewise, "immu-
nologically active" defines the capability of the natural, 
recombinant or synthetic s ABC transporter ligand, or any 
oligopeptide thereof, to induce a specific immune response in 
appropriate animals or cells and to bind with specific anti-
bodies. 
"Coding sequence" refers to a nucleotide sequence that 
codes for a specific amino acid sequence. "Regulatory 
sequences" refer to nucleotide sequences located upstream ( 5' 
non-coding sequences), within, or downstream (3' non-cod-
ing sequences) of a coding sequence, and which influence the 
transcription, RNA processing or stability, or translation of 
the associated coding sequence. Regulatory sequences may 
include promoters, translation leader sequences, intrans, and 
polyadenylation recognition sequences. 
The term "derivative" as used herein refers to the chemical 
modification of a ABC transporter ligand. Illustrative of such 
modifications would he replacement of hydrogen by an alkyl, 
acyl, or amino group, A polypeptide derivative would retain 
essential biological characteristics of a natural polypeptide. 
The term "effective amount" or "therapeutically effective 
amount" means a dosage sufficient to provide treatment of the 
disease state being treated or to otherwise provide a desired 
pharmacologic and/or physiologic effect. The precise dosage 
will vary according to a variety of factors such as subject-
dependent variables (e.g., age, immune system health, etc.), 
the cause of the injury (e.g., the species of scorpion), the 
disease (e.g., the nature of the effect on ABC transporters 
caused by the disease), and the treatment being effected. In 
the case of a scorpion sting, an "effective amount" is that 
amount necessary to substantially improve the likelihood of 
treating the sting, in particular that amount which improves 
the likelihood of successfully preventing effects of the toxins 
on the subject, relieving or minimizing toxin effects, or arrest-
ing any complications caused or exacerbated by the toxin. 
Where the scorpion toxin is used as an insecticide or pesti-
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cide, an "effective amount" is that amount necessary to kill 
the insect or pest, or otherwise effect the behavior of the insect 
or pest in such a way that it no longer performs or causes 
undesired events or activities, e.g. consume or damage plants. 
By "envenomation" is meant when a subject is bitten or 
stung by a scorpion. 
The terms "individual," "host," "subject," and "patient" are 
used interchangeably herein, and refer to a mammal, includ-
ing, but not limited to, murines, simians, humans, mammalian 
farm animals, mammalian sport animals, and mammalian 
pets. 
As used herein the term "isolated" is meant to describe a 
compound of interest (e.g., either a polynucleotide or a 
polypeptide) that is in an environment different from that in 
which the compound naturally occurs e.g. separated from its 
natural milieu such as by concentrating a peptide to a con-
centration at which it is not found in nature. "Isolated" is 
meant to include compounds that are within samples that are 
substantially enriched for the compound of interest and/or in 
which the compound of interest is partially or substantially 
purified. 
"Polypeptide" as used herein refers to an oligopeptide, 
peptide, modified polypeptide, or protein. Where "polypep-
tide" is recited-herein to refer to an amino acid sequence of a 
naturally-occurring protein molecule, "polypeptide" and like 
terms are not meant to limit the amino acid sequence to the 
complete, native amino acid sequence associated with the 
recited protein molecule, but is meant to encompass ana-
logues, degenerate substitutions, etc. 
"Polynucleotide" and "nucleic acid" as used interchange-
ably herein refer to an oligonucleotide, nucleotide, and frag-
ments or portions thereof, as well as to peptide nucleic acids 
(PNA), fragments, portions or antisense, molecules thereof, 
and to DNA or RNA of genomic or synthetic origin which can 
be single- or double-stranded, and represent the sense or 
antisense strand. Where "polynucleotide" or "nucleic acid" is 
used to refer to a specific polynucleotide sequence (e.g., 
encoding a scorpion toxin such as GaTxl), the terms are 
meant to encompass polynucleotides that encode a polypep-
tide that is functionally equivalent to the recited polypeptide, 
e.g., polynucleotides that are degenerate variants, or poly-
nucleotides that encode biologically active variants or frag-
ments of the recited polypeptide. 
As used herein, the term "prodrug" refers to an active agent 
chemically transformed into a per se inactive derivative 
which, by virtue of chemical or enzymatic attack, is converted 
to the parent agent within the body before or after reaching the 
site of action. Prodrugs are frequently (though not necessar-
ily) pharmacologically inactive until converted to the parent 
drug. A prodrug may be converted into the parent drug by 
various mechanisms, including enzymatic processes and 
metabolic hydrolysis. Examples of prodrugs include, but are 
not limited to, ester and amide prodrugs; polyethylene glycol 
prodrugs (with and without a linker); N-acyl amine prodrugs, 
dihydropyridine prodrugs, 2-hydroxybenzamide prodrugs; 
carbamate prodrugs; peptide prodrugs; Mannich bases, amd 
Schiff bases. 
"Protein Transduction Domain" or PTD refers to a 
polypeptide, polynucleotide, carbohydrate, or organic or 
inorganic compounds that facilitates traversing a lipid 
bilayer, micelle, cell membrane, organelle membrane, or 
vesicle membrane. A PTD attached to another molecule 
facilitates the molecule traversing membranes, for example 
going from extracellular space to intracellular space, or cyto-
sol to within an organelle. Exemplary PTDs include but are 
not limited to HIV TATYGRKKRRQRRR (SEQ. ID N0:3) 
or RKKRRQRRR (SEQ. ID N0:4); 11 Arginine residues, or 
8 
positively charged polypeptides or polynucleotides having 
8-15 residues, preferably 9-11 residues. 
"Subjects" or "patients" as used herein, encompasses any 
subject or patient amenable to application of the methods of 
treatment or diagnostic methods. Mammalian subjects and 
patients, particularly human, subjects or patients, are of par-
ticular interest. 
As used herein, the term "substantially purified" refers to a 
compound (e.g., either a polynucleotide or a polypeptide) that 
10 is removed from its natural environment and is at least 60% 
free, preferably 75% free, and most preferably 90% free from 
other components with which it is naturally associated. 
As used herein, the terms "treatment," "treating," and the 
like, refer to obtaining a desired pharmacologic and/or physi-
15 ologic effect. The effect may be prophylactic in terms of 
completely or partially preventing a symptom thereof and/or 
may be therapeutic in terms of a partial or complete cure for 
an adverse affect attributable to the condition. "Treatment," as 
used herein, covers any treatment of an injury in a mammal, 
20 particularly in a human, and includes: (a) preventing the 
injury, arresting any complications, and minimizing its 
effects; (b) relieving the symptoms; ( c) preventing the disease 
from occurring in a subject which may be predisposed to the 
disease but has not yet been diagnosed as having it; ( d) inhib-
25 iting the disease, i.e., arresting its development; and ( e) reliev-
ing the disease, i.e., causing regression of the disease. 
A "substantial portion" of an amino acid or nucleotide 
sequence refers to an amino acid or a nucleotide sequence that 
is sufficient to afford putative identification of the protein or 
30 gene that the amino acid or nucleotide sequence comprises. 
Amino acid and nucleotide sequences can be evaluated either 
manually by one skilled in the art, or by using computer-based 
sequence comparison and identification tools that employ 
algorithms such as BLAST (Basic Local Alignment Search 
35 Tool; Altschul et al, (1993) J. Mo!. Biol. 215:403410). In 
general, a sequence of ten or more contiguous amino acids or 
thirty or more contiguous nucleotides is necessary in order to 
putatively identify a polypeptide or nucleic acid sequence as 
homologous to a known protein or gene. Moreover, with 
40 respect to nucleotide sequences, gene-specific oligonucle-
otide probes comprising 30 or more contiguous nucleotides 
may be used in sequence-dependent methods of gene identi-
fication (e.g., Southern hybridization) and isolation (e.g., in 
situ hybridization of bacterial colonies or bacteriophage 
45 plaques). In addition, short oligonucleotides of 12 or more 
nucleotides may be used as amplification primers in PCR in 
order to obtain a particular nucleic acid fragment comprising 
the primers. Accordingly, a "substantial portion" of a nucle-
otide sequence comprises a nucleotide sequence that will 
50 afford specific identification and/or isolation of a nucleic acid 
fragment comprising the sequence. The instant specification 
involves amino acid and nucleotide sequences encoding 
polypeptides that comprise one or more particular scorpion 
toxin proteins. The skilled artisan, having the benefit of the 
55 sequences as reported herein, may now use all or a substantial 
portion of the disclosed sequences for purposes known to 
those skilled in this art. Accordingly, the instant invention 
comprises the complete sequences as reported in the accom-
panying Sequence Listing, as well as substantial portions of 
60 those sequences as defined above. 
As used herein, "substantially similar" refers to nucleic 
acid fragments wherein, changes in one or more nucleotide 
bases results in substitution of one or more amino acids, but 
do not affect the functional properties of the polypeptide 
65 encoded by the polynucleotide sequence. "Substantially 
similar" also refers to modifications of the nucleic acid frag-
ments of the instant invention such as deletion or insertion of 
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one or more nucleotides that do not substantially affect the 
functional properties of the resulting protein molecule. It is 
therefore understood that the invention encompasses more 
than the specific exemplary sequences. 
10 
concern causing thousands of deaths per year, in diarrhea-
predominant inflammatory bowel syndrome, and in autoso-
mal dominant polycystic kidney disease (ADPKD), the most 
common inherited nephropathy and fourth leading cause of 
end-stage renal disease in the United States. Thus, the dis-
closed peptide ligands or variants thereof can be used to treat 
diseases or symptoms related to over-activity of CFTR. 
The domain architecture of CFTR (FIG. la), with two sets 
of membrane-spanning domains, two nucleotide-binding 
Moreover, substantially similar nucleic acid fragments 
may also be characterized by their ability to hybridize. Esti-
mates of such homology are provided by either DNA-DNA or 
DNA-RNA hybridization under conditions of stringency as is 
well understood by those skilled in the art (Hames and Hig-
gins, Eds. (1985) Nucleic Acid Hybridisation, IRL Press, 
Oxford, UK,). Stringency conditions can be adjusted to 
screen for moderately similar fragments, such as homologous 
sequences from distantly related organisms, to highly similar 
fragments, such as genes that duplicate functional enzymes 
from closely related organisms. Post-hybridization washes 
determine stringency conditions. One set of preferred condi-
tions uses a series of washes starting with 6xSSC, 0.5% SDS, 
10 domains (NBDs), and a separate regulatory (R) domain, 
places CFTR in the superfamily of ABC Transporters, 
although it is the sole member ofthis family that forms an ion 
channel. GaTxl selectively and reversibly inhibits CFTR 
with higher affinity than other known modulators of this 
at room temperature for 15 min, then repeated with 2xSSC, 
0.5% SDS at 45° C. for 30 min, and then repeated twice with 
0.2xSSC, 0.5% SDS at 50° C. for 30 min. A more preferred 
set of stringent conditions uses higher temperatures in which 
the washes are identical to those above except for the tem-
perature of the final two 30 min washes in 0.2xSSC, 0.5% 
SDS was increased to 60° C. Another preferred set of highly 
stringent conditions uses two final washes in O.lxSSC, 0.1 % 
SDS at 65° C. 
15 channel by interacting with the protein in the interburst closed 
state, locking channels closed for minutes at a time. The 
estimated Kn for GaTxl-mediated inhibition ofCFTR is 25 
nM in the presence of 0.2 mM ATP. 
Another embodiment provides a purified peptide isolated 
20 from the venom of Leiurus quinquestriatus hebraeus wherein 
the peptide interacts with CFTR when CFTR is in the inter-
burst closed state. The peptide reversibly interacts or binds 
with the chloride channel in the closed state and keeps the 
channel in the closed stated for about 1 second to about 1,2, or 
25 3 minutes. 
Another embodiment provides an ABC transporter ligand 
having an amino acid sequence SEQ ID NO: 1, or a biologi-
cally active or immunogenic fragment thereof. 
Yet another embodiment provides a nucleic acid encoding 
30 a polypeptide having at least 0.98% sequence identity to SEQ 
ID NO: 1. The polynucleotide sequence can substituted with 
the appropriate nucleic acids that encode analogs of the pep-
tide based on codon degeneracy as are known in the art. 
Substantially similar nucleic acid fragments may also be 
characterized by the percent identity of the amino acid 
sequences that they encode to the amino acid sequences dis-
closed herein, as determined by algorithms commonly 
employed by those skilled in this art. Suitable nucleic acid 
fragments (isolated polynucleotides of the present invention) 
encode polypeptides that are at least about 70% identical, 
preferably at least about 80% identical to the amino acid 
sequences reported herein. Preferred nucleic acid fragments 
encode amino acid sequences that are at least about 85% 
identical to the amino acid sequences reported herein. More 
preferred nucleic acid fragments encode amino acid 
sequences that are at least about 90% identical to the amino 
acid sequences reported herein. Most preferred are nucleic 40 
acid fragments that encode amino acid sequences that are at 
least about 95%, 98%, 99% or more identical to the amino 
acid sequences reported herein. 
Yet another embodiment provides a nucleic acid, having at 




TTG-TGT-AAT-AGG (SEQ ID N0:2). 
B. Variants of ABC Transporter Ligands 
1. Conservative Substitutions of Amino Acids 
Another embodiment provides nucleic acid molecules that 
encode a polypeptide having a conservative amino acid 
change, compared with SEQ ID NO: 1. For example, variants 
II. ABC Transporter Ligands 
A. Peptide Ligands 
45 can be obtained that contain one or more amino acid substi-
tutions of SEQ ID NO:l, in which an alkyl amino acid is 
substituted for an alkyl amino acid in a GaTxl amino acid 
sequence, an aromatic amino acid is substituted for an aro-
matic amino acid in a GaTxl amino acid sequence, a sulfur-
One embodiment provides an isolated peptide having at 
least 80% sequence identity to 1CGPCFTTDHQMEQK-
CAECCGGIGKCYGPQCLCNR34 (SEQ ID NO:l), a vari-
ant, derivative or prodrug thereof. The isolated peptide, also 
referred to as GaTxl, is isolated from the venom of Leiurus 
quinquestriatus hebraeus, the giant Israeli scorpion. The pep-
tide ligand is believed to have a molecular mass of about 3.7 
kDa (FIG. Sa) and binds to ABC transporters, in particular 55 
chloride channels. In one embodiment, the ABC transporter is 
cystic fibrosis transmembrane conductance regulator 
(CFTR). 
50 containing amino acid is substituted for a sulfur-containing 
amino acid in a GaTxl amino acid sequence, a hydroxy-
containing amino acid is substituted for a hydroxy-containing 
amino acid in a GaTxl amino acid sequence, an acidic amino 
acid is substituted for an acidic amino acid in a GaTxl amino 
The CFTR protein forms a c1- channel which is activated 
by protein kinase A (PKA)-mediated phosphorylation plus 60 
ATP binding and hydrolysis, and is expressed predominantly 
in epithelial cells; CFTR is also expressed in ventricular 
myocytes and multiple regions of the brain. Mutations in 
CFTR are associated with cystic fibrosis, the most common 
lethal autosomal recessive disease among Caucasians, affect- 65 
ing >60,000 individuals worldwide. Over-activity of CFTR 
plays a key role in secretory diarrhea, a worldwide health 
acid sequence, a basic amino acid is substituted for a basic 
amino acid in a GaTxl amino acid sequence, or a dibasic 
monocarboxylic amino acid is substituted for a di basic mono-
carboxylic amino acid in a GaTxl amino acid sequence. 
Among the common amino acids, for example, a "conserva-
tive amino acid substitution" is illustrated by a substitution 
among amino acids within each of the following groups: (1) 
glycine, alanine, valine, leucine, and isoleucine, (2) phenyla-
lanine, tyrosine, and tryptophan, (3) serine and threonine, (4) 
aspartate and glutamate, (5) glutamine and asparagine, and 
( 6) lysine, arginine and histidine. The BLOSUM62 table is an 
amino acid substitution matrix derived from about 2,000 local 
multiple alignments of protein sequence segments, represent-
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desired non-naturally occurring amino acid(s) (e.g., 2-aza-
phenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 
4-fluorophenylalanine ). The non-naturally occurring amino 
acid is incorporated into the protein in place of its natural 
counterpart. See, Koide et al., Biochem. 33:7470 (1994). 
Naturally occurring amino acid residues can be converted to 
non-naturally occurring species by in vitro chemical modifi-
cation. Chemical modification can be combined with site-
ing highly conserved regions of more than 500 groups of 
related proteins (Henikoff and Henikoff, Proc. Nat'! Acad. 
Sci. USA 89:10915 (1992)). Accordingly, the BLOSUM62 
substitution frequencies can be used to define conservative 
amino acid substitutions that may be introduced into the 5 
amino acid sequences of the disclosed peptide ion channel 
inhibitors. Although it is possible to design amino acid sub-
stitutions based solely upon chemical properties (as discussed 
above), the language "conservative amino acid substitution" 
preferably refers to a substitution represented by a BLO-
SUM62 value of greater than -1. For example, an amino acid 
substitution is conservative ifthe substitution is characterized 
directed mutagenesis to further expand the range of substitu-
10 tions (Wynn and Richards, Protein Sci. 2:395 (1993)). 
by a BLOSUM62 value of 0, 1, 2, or 3. According to this 
system, preferred conservative amino acid substitutions are 
characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 15 
3), while more preferred conservative amino acid substitu-
tions are characterized by a BLOSUM62 value of at least 2 
(e.g., 2 of3). 
Particular variants ofGaTxl are characterized by having at 
least 70%, at least 80%, at least 90%, at least 95% or greater 20 
than 95% sequence identity to die corresponding amino acid 
sequence (e.g., SEQ ID NO:l), wherein the variation in 
amino acid sequence is due to one or more conservative 
amino acid substitutions. 
3. Non-Conservative Amino Acid Substitutions 
A limited number of non-conservative amino acids, amino 
acids that are not encoded by the genetic code, non-naturally 
occurring amino-acids, and unnatural amino acids may be 
substituted for GaTxl amino acid residues. 
Essential amino acids in the polypeptides can be identified 
according to procedures known in the art, such as site-di-
rected mutagenesis or alanine-scanning mutagenesis (Cun-
ningham and Wells, Science 244: 1081 (1989), Bass et al., 
Proc. Nat'! Acad. Sci. USA 88:4498 (1991), Coombs and 
Corey, "Site-Directed Mutagenesis and Protein Engineer-
ing," in Proteins: Analysis and Design, Angeletti (ed.), pages 
259-311 (Academic Press, Inc. 1998)). In the latter technique, 
single alanine mutations are introduced at every residue in the 
Conservative amino acid changes in a GaTxl gene can be 
introduced, for example, by substituting nucleotides for the 
nucleotides recited in SEQ ID N0:2. Such "conservative 
amino acid" variants can be obtained by oligonucleotide-
directed mutagenesis, linker-scarming mutagenesis, 
mutagenesis using the polymerase chain reaction, and the like 
(see Ausubel (1995) at pages 8-10 to 8-22; and McPherson 
(ed.), Directed Mutagenesis: A Practical Approach (IRL 
Press 1991 )). A variant GaTxl polypeptide can be identified 
25 molecule, and the resultant mutant molecules are tested for 
biological activity to identify amino acid residues that are 
critical to the activity of the molecule. See also, Hilton et al., 
J. Biol. Chem. 271 :4699 (1996). 
Although sequence analysis can be used to further define 
by the ability to specifically bind anti-GaTxl antibodies. 
30 the GaTxl anion channel binding region, amino acids that 
play a role in GaTxl binding activity (such as binding of 
GaTxl to CFTR, or to an anti-GaTxl antibody) can also be 
determined by physical analysis of structure, as determined 
by such techniques as nuclear magnetic resonance, crystal-
2. Variants Containing Non-Naturally Occurring Amino 
Acid Residues 
35 lography, electron diffraction or photoaffinity labeling, in 
conjunction with mutation of putative contact site amino 
acids. See, for example, de Vos et al., Science 255:306 (1992), 
Smith eta!., J. Mo!. Biol. 224:899 (1992), and Wlodaveretal., 
The disclosed peptide antagonists can also comprise non-
naturally occurring amino acid residues. Non-naturally 
occurring amino acids include, without limitation, trans-3-
methylproline, 2,4-methanoproline, cis-4-hydroxyproline, 40 
trans-4-hydroxyproline, N-methylglycine, allo-threonine, 
methylthreonine, hydroxyethylcysteine, hydroxyethylho-
mocysteine, nitroglutamine, homoglutamine, pipecolic acid, 
thiazolidine carboxylic acid, dehydroproline, 3- and 4-meth-
ylproline, 3,3-dimethylproline, tert-leucine, norvaline, 2-aza-
phenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 
4-fluorophenylalanine. Several methods are known in the art 
for incorporating non-naturally occurring amino acid resi-
dues into proteins. For example, an in vitro system can be 
employed wherein nonsense mutations are suppressed using 
chemically aminoacylated suppressor tRNAs. Methods for 
synthesizing amino acids and aminoacylating tRNA are 
known in the art. Transcription and translation of plasmids 
containing nonsense mutations is typically carried out in a 
cell-free system comprising an E. coli S30 extract and com-
mercially available enzymes and other reagents. Proteins are 
purified by chromatography. See, for example, Robertson et 
al., J.Am. Chem. Soc.113:2722 (1991), Ellman eta!., Meth-
ods Enzymol. 202:301 (1991), Chung et al. Science 259:806 
(1993), and Chung et al., Proc. Nat'!. Acad. Sci, USA 
90:10145 (1993). 
In a second method, translation is carried out in Xenopus 
oocytes by microinjection of mutated mRNA and chemically 
aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. 
Chem. 271:19991 (1996)). Within a thirdmethod,E. coli cells 
are cultured in the absence of a natural amino acid that is to be 
replaced (e.g., phenylalanine) and in the presence of the 
FEBS Lett. 309:59 (1992). 
Multiple-amino acid substitutions can be made and tested 
using known methods of mutagenesis and screening, such as 
those disclosed by Reidhaar-Olson and Sauer (Science 241: 
53 (1988)) or Bowie and Sauer (Proc. Nat'! Acad. Sci. USA 
86:2152 (1989). Briefly, these authors disclose methods for 
45 simultaneously randomizing two or more positions in a 
polypeptide, selecting for functional polypeptide, and then 
sequencing the mutagenized polypeptides to determine the 
spectrum of allowable substitutions at each position. Other 
methods that can be used include phage display (e.g., Low-
50 manet al., Biochem. 30:10832 (1991). Ladner eta!., U.S. Pat. 
No. 5,223,409, Huse, international publication No. WO 
92/06204, and region-directed mutagenesis (Derbyshire et 
al., Gene 46: 145 (1986), and Ner et al., DNA 7: 127, (1988)). 
Moreover, GaTxl labeled with biotin or FITC can be used for 
55 expression cloning ofGaTxl ligands. 
Variants of the disclosed GaTxl nucleotide (SEQ ID 
N0:2) and polypeptide (SEQ ID NO: 1) sequences can also be 
generated through DNA shuffling as disclosed by Stemmer, 
Nature370:389 (1994), Stemmer, Proc. Nat'!Acad. Sci. USA 
60 91:10747 (1994), and international publication No. WO 
97 /20078. Briefly, variant DNA molecules are generated by 
in vitro homologous recombination by random fragmentation 
of a parent DNA followed by reassembly using PCR, result-
ing in randomly introduced, point mutations. This technique 
65 can be modified by using a family of parent DNA molecules, 
such as allelic variants or DNA molecules from different 
species, to introduce additional variability into the process. 
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Selection or screening for the desired activity, followed by tides can be identified using standard methods (see, for 
additional iterations of mutagenesis and assay provides for example, Geysen et al., Proc. Nat'! Acad. Sci. USA 81 :3998; 
rapid "evolution" of sequences by selecting for desirable (1983)). 
mutations while simultaneously selecting against detrimental In contrast, polypeptide fragments or peptides may include 
changes. 5 an "antigenic epitope," which is a regionofa protein molecule 
Mutagenesis methods as disclosed herein can be combined to which an antibody can specifically bind. Certain epitopes 
with high-throughput, automated screening methods to detect consist of a linear or contiguous stretch of amino acids, and 
activity of cloned, mutagenized polypeptides in host cells. the antigenicity of such .an epitope is not disrupted by dena-
Mutagenized DNA molecules that encode biologically active turing agents. It is known in the art that relatively short syn-
10 thetic peptides that can mimic epitopes of a protein can be polypeptides, or polypeptides that bind with anti-GaTxl anti-
used to stimulate the production of antibodies against the 
bodies, can be recovered from the host cells and rapidly 
protein (see, for example, Sutcliffe et al., Science 219:660 
sequenced using modern equipment. These methods allow (1983)). Accordingly, antigenic epitope-bearing peptides and 
the rapid determination of the importance Of individual polypeptides of the present invention are useful to raise anti-
amino acid residues in a polypeptide of interest, and can be 15 bodies that bind with the polypeptides described herein. 
applied to polypeptides of unknown structure. Antigenic epitope-hearing peptides and polypeptides can 
4. Fragments of ABC Transporter Ligands contain at least four to ten amino acids, at least ten to fifteen 
Another embodiment provides "functional fragments" of amino acids, or about 15 to about 30 amino acids of an amino 
GaTxl polypeptides and nucleic acid molecules encoding acid sequence disclosed herein. Such epitope-bearing pep-
such functional fragments. Routine deletion analyses of 20 tides and polypeptides can be produced by fragmenting a 
nucleic acid molecules can be performed to obtain functional GaTxl polypeptide, or by chemical peptide synthesis, as 
fragments of a nucleic acid molecule that encodes a GaTxl described herein. Moreover, epitopes can be selected by 
polypeptide. As an illustration, DNA molecules having the phage display ofrandom peptide libraries (see, for example, 
nucleotide sequence of SEQ ID N0:2 can be digested with Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993), and 
Bal31 nuclease to obtain a series of nested deletions. The 25 Cortese et al., Curr. Opin. Biotechnol. 7:616 (1996)). Stan-
fragments are then inserted into expression vectors in proper dardmethods for identifying epitopes and producing antibod-
reading frame, and the expressed polypeptides are isolated ies from small peptides that comprise ah epitope are 
and tested for the ability to bind anti-GaTxl antibodies. One described, for example, by Mole, "Epitope Mapping," in 
alternative to exonuclease digestion is to use-oligonucle- Methods in Molecular Biology, Vol. 10, Manson (ed.), pages 
otide-directed mutagenesis to introduce deletions or stop 30 105-116 (The Humana Press, Inc. 1992), Price, "Production 
codons to specify production of a desired fragment. Alterna- and Characterization of Synthetic Peptide-Derived Antibod-
ies," in Monoclonal Antibodies: Production, Engineering, 
tively, particular fragments of a GaTxl gene can be synthe-
and Clinical Application, Ritter and Ladyman (eds.), pages 
sized using the polymerase chain reaction. 60-84 (Cambridge University Press 1995), and Coligan et al. 
This general approach is exemplified by studies on the 35 (eds.), Current Protocols in Immunology, pages 9.3.1-9.3.5 
truncation at either or both termini of interferons have been and pages 9.4.1-9.4.11. (John Wiley & Sons 1997). 
summarized by Horisberger and Di Marco, Pharmac. Ther. For any GaTxl polypeptide, including variants and fusion 
66:507 (1995). Moreover, standard techniques for functional proteins, one ofordinary skill in the art can readily generate a 
analysis of proteins are described by, for example, Treuter et fully degenerate polynucleotide sequence encoding that vari-
al., Malec. Gen. Genet. 240: 113 (1993), Content et al., 40 ant. Moreover, those of skill in the art can use standard soft-
"Expression and preliminary deletion, analysis of the 42 kDa ware to devise GaTxl variants based upon the nucleotide and 
2-5A synthetase induced by human interferon," in Biological amino acid sequences described herein. Accordingly, the 
Interferon Systems, Proceedings of ISIR-TNO Meeting on present invention includes a computer-readable medium 
interferon Systems, Cantell (ed.), pages 65-72 (Nijhoff encoded with a data structure that provides at least one of the 
1987), Herschman, "The EGF Receptor," in Control of Ani- 45 following sequences: SEQ ID NO: 1 and SEQ ID N0:2. Suit-
mal Cell Proliferation, Vol. 1, Boynton et al., (eds.) pages able forms of computer-readable media include magnetic 
169-199 (Academic Press 1985), Coumailleau et al., J. Biol. media and optically-readable media. Examples of magnetic 
Chem. 270:29270 (1995); Fukunaga et. al., J. Biol. Chem. media include a hard or fixed drive, a random access memory 
270:25291 (1995); Yamaguchi et al., Biochem. Pharmacol (RAM) chip, a floppy disk, digital linear tape (DLT), a disk 
50:1295 (1995), and Meisel et al., Plant Malec. Biol. 30: 1 50 cache, and a ZIP disk. Optically readable media are exempli-
(1996). fied by compact discs (e.g., CD-read only memory (ROM), 
Another embodiment provides functional fragments of a CD-rewritable (RW), and CD-recordable), and digital versa-
GaTxl gene that have amino acid changes, compared with tile/video discs (DVD) (e.g., DVD-ROM, DVD-RAM, and 
SEQ ID NO: 1. A variant GaTxl gene can be identified, on the DVD+RW). 
basis of structure by determining the level of identity with 55 B. Peptidomimetics 
disclosed nucleotide and amino acid sequences, as discussed Another embodiment provides peptidomimetics of the 
above. An alternative approach to identifying a variant gene ABC transporter ligands, for example SEQ ID NO: 1. Pepti-
on the basis of structure is to determine whether a nucleic acid domimetics, as used herein, refers to molecules bearing iden-
molecule encoding a potential variant GaTxl gene can tifiable resemblance to the scorpion venom polypeptide, for 
hybridize to a nucleic acid molecule comprising a nucleotide 60 example SEQ ID NO: 1 that, as a ligand of a chloride chamiel, 
sequence, such as SEQ ID N0:2. can imitate or inhibit the effect of the scorpion venom 
One embodiment provides polypeptide fragments or pep- polypeptide. Exemplary ABC transporter ligand peptidomi-
tides having an epitope-bearing portion of a GaTxl polypep- metics have increased bioavailability, biostability, bioeffi-
tide described herein. Such fragments or peptides may com- ciency, and/or bioselectivity against the biological target of 
prise an "immunogenic epitope," which is a part of a protein 65 the parent peptide, for example CFTR. 
that elicits an antibody response when the entire protein is Examples of peptidomimetics have been Isolated as natu-
used as an immunogen. Immunogenic epitope-bearing pep- ral products, synthesized as libraries from, novel subunits, 
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and designed on the basis of X-ray crystallographic studies 
and through an intricate knowledge of the biological mode of 
action of natural peptides. Examples of such peptidomimetic 
materials are described in Moore et al., Chem. Rev. 101(12), 
3893-4012 (2001), Peptidomimetics that structurally and/or 
functionally resemble a polypeptide embodiment may be 
made. Several approaches to make peptidomimetics that 
resemble polypeptides have been described (see, e.g., U.S. 
Pat. Nos. 5,288,707; 5,552,534; 5,811,515; 5,817,626; 5,817, 
16 
C. Vectors and Nucleic Acids Encoding ABC Transporter 
Ligands 
Another embodiment provides nucleic acid compositions 
that may encode all or a biologically active part of GaTxl, e.g. 
the nucleic acids may encode all or part of SEQ ID NO: 1, and 
may be synthesized oligonucleotides, mRNA, cDNA, or 
genomic DNA. These polynucleotides can be used, when in a 
recombinant expression vector, to produce the encoded 
879; 5,821,231; and 5,874,529). 10 
GaTxl or functional fragment thereof. They are also useful as 
hybridization probes in methods of detecting scorpion venom 
toxins gene expression, specifically transcription. Accord-Peptidomimetic materials of the disclosed ABC trans-
porter ligands can be generated to fall within one of four 
categories of known peptidomimetics: a-peptides, ~-pep­
tides, y-peptides, and o-peptides, Copolymers of these pep-
15 
tides can also be used. 
ingly, one embodiment provides recombinant vectors and 
host cells containing a polynucleotide encoding GaTxl. 
Another embodiment provides polynucleotides coding for 
a scorpion venom toxin polypeptide sequence set forth in 
SEQ ID NO: 1 an identifying sequence thereof. An "identify-
ing sequence" is a contiguous sequence of residues at least 
about 10 nucleotides (nt) to about 20 nt in length, usually at 
Examples of a-peptide peptidomimetics include, but are 
not limited to, N,N'-linked oligoureas, oligopyrrolinones, 
oxazolidin-2-ones, azatides and azapeptides. 
Examples of ~-peptides include, but are not limited to, 
~-peptide foldamers, a-aminoxy acids, sulfur-containing 
~-peptide analogues, and hydrazino peptides. 
Examples of y-peptides include, but are not limited to, 
y-peptide foldamers, oligoureas, oligocarbamates, and phos-
phodiesters. 
Examples of o-peptides include, but are not limited to, 
alkene-based o-amino acids and carbopeptoids, such as pyra-
nose-based carbopeptoids and furanose-based carbopep-
toids. 
Other peptidomimetics of the ABC transporter ligands can 
be oligomers having backbones which can adopt helical or 
sheet conformations. Example of such compounds include, 
hut are not limited to, compounds having backbones utilizing 
bipyridine segments, compounds having backbones utilizing 
solvophobic interactions, compounds having backbones uti-
lizing side chain interactions, compounds having backbones 
utilizing hydrogen bonding interactions, and compounds 
having backbones utilizing metal coordination. 
20 least about 40 nt to about 55 nt in length, that uniquely 
identifies the provided sequence. Encompassed in the term 
"scorpion venom toxin-encoding polynucleotide" are poly-
nucleotides comprising about 10, 20, 25, 50, 72 contiguous 
nucleotides coding for SEQ ID NO:l, including the entire 
25 coding region of SEQ ID N0:2. 
"Hybridization" refers to the association of two nucleic 
acid sequences to one another by hydrogen bonding. Two 
sequences will be placed in contact with one another under 
conditions that favor hydrogen bonding. Factors that affect 
30 this bonding include: the type and volume of solvent; reaction 
temperature; time of hybridization; agitation; agents to block 
the non-specific attachment of the liquid phase sequence to 
the solid support (Denhardt's reagent or BLOTTO); concen-
tration of the sequences; use of compounds to increase the 
35 rate of association of sequences ( dextran sulfate or polyeth-
ylene glycol); and the stringency of the washing conditions 
following hybridization. See Sambrook, et al., Molecular 
Cloning: A Laboratory Manual, 2nd Ed. (1989), Volume 2, 
Examples of compounds containing backbones utilizing 
bipyridine segments include, but are not limited to, oligo 40 
(pyridine-pyrimidines), oligo(pyridine-pyrimidines) with 
hydrazal linkers, and pyridine-pyridazines. 
chapter 9, pages 9.47 to 9.57. 
"Stringency" refers to conditions in a hybridization reac-
tion that favor association of very similar sequences over 
sequences that differ. For example, the combination of tem-
perature and salt concentration should be chosen that is 
approximately 120 to 200° C. below the calculated Tm of the 
Examples of compounds containing backbones utilizing 
solvophobic interactions include, but are not limited to, oli-
goguanidines, aedamers (structures which take advantage of 
the stacking properties of aromatic electron donor-acceptor 
interactions of covalently linked subunits) such as oligomers 
containing 1,4,5,8-naphthalene-tetracarboxylic diimide rings 
and 1,5-dialkoxynaphthalene rings, and cyclophanes such as 
substituted N-benzyl phenylpyridinium cyclophanes. 
Examples of compounds containing backbones utilizing 
side chain interactions include, but are not limited to, olig-
othiophenes such as oligothiophenes with chiral p-phenyl-
oxazoline side chains, and oligo(m-phenylene-ethynylene )s. 
Examples of compound containing backbones utilizing 
hydrogen bonding interactions include, but are not limited to, 
aromatic amide backbones such as oligo(acylated 2,2',-bipy-
ridine-3,3',-diamine )s and oligo(2,5-bis[2-aminophenyl] 
pyrazine)s, diaminopyridine backbones templated by cyanu-
rate, and phenylene-pyridine-pyrimidine ethynylene 
backbones templated by isophthalic acid. 
Examples of compounds containing backbones utilizing 
metal coordination include, but are not limited to, zinc bili-
nones, oligopyridines complexed with Co(II), Co(III), Cu(II), 
Ni(II), Pd(II), Cr(III), or Y(III), oligo(m-phenylene ethy-
nylene )s containing metal-coordinating cyano groups, and 
hexapyrrins. 
45 hybrid under study. The temperature and salt conditions can 
often be determined empirically in preliminary experiments 
in which samples of genomic DNA immobilized on filters are 
hybridized to the sequence of interest and then washed under 
conditions of different stringencies. See Sambrook, et al., 
50 supra, at page 9.50. 
Variables to consider when performing, for example, a 
Southern blot are (1) the complexity of the DMA being blot-
ted and (2) the homology between the target and the 
sequences being detected. The total amount of the polynucle-
55 otides to be studied can vary a magnitude of 10, from 0.1to1 
µg for a plasmid or phage digest to 10-9 to 10-3 µg for a single 
copy gene in a highly complex eukaryotic genome. For lower 
complexity polynucleotides, substantially shorter blotting, 
hybridization, and exposure times, a smaller amount of start-
60 ing polynucleotides, and lower specific activity of a target 
polynucleotide can be used. For example, a single-copy yeast 
gene can be detected with an exposure time of only 1 hour 
starting with 1 µg of yeast DNA, blotting for two hours, and 
hybridizing for 4 8 hours with a target polynucleotide radio-
65 labeled with 108 cpm/µg. For a single-copy mammalian gene 
a conservative approach would start with 10 µg of DNA, blot 
overnight, and hybridize overnight in the presence of 10% 
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dextran sulfate using a target polynucleotide radiolabeled 
with greater than 108 cpm/µg, resulting in an exposure time of 
about 24 hours. 
Several factors can affect the melting temperature (Tm) of 
a DNA-DNA hybrid between the target and sequence ofinter-
est, and consequently, the appropriate conditions for hybrid-
ization and washing. In many cases the target is not 100% 
homologous to the fragment. Other commonly encountered 
variables include the length and total G+C content of the 
hybridizing sequences and the ionic strength and formamide 10 
content of the hybridization buffer. The effects of all of these 
factors can be approximated by a. single equation: 
Tm=81+16.6(log lOCi)+0.4[% G+C)]-0.6(% forma-
mide)-600/n-1.5(% mismatch), where Ci is the salt concen-
tration (monovalent ions) and n is the length of the hybrid in 15 
base pairs (slightly modified from Meinkoth and Wahl, 
(1984) Anal Biochem. 138:267 284). 
In designing a hybridization experiment, some factors 
affecting nucleic acid hybridization can be conveniently 
altered. The temperature of the hybridization and washes and 20 
the salt concentration during the washes are the simplest to 
adjust. As the temperature of the hybridization increases (i.e. 
stringency), it becomes less likely for hybridization to occur 
between strands that are nonhomologous, and as a result, 
background decreases. If the labeled probe is not completely 25 
homologous with the immobilized fragment (as is frequently 
the case in gene family and interspecies hybridization experi-
ments), the hybridization temperature must be reduced, and 
background will increase. The temperature of the washes 
affects the intensity of the hybridizing band and the degree of 30 
background in a similar manner. The stringency of the washes 
is also increased with decreasing salt concentrations. 
In general, convenient hybridization temperatures in the 
presence of 50% formamide are 42° C. for a target polynucle-
otide with 95% to 100% sequence identity to the sequence to 35 
be detected, 37° C. for 90% to 95% sequence identity, and 32° 
C. for 85% to 90% sequence identity. For lower percentage 
sequence identity, formamide content should be lowered and 
temperature adjusted accordingly, using the equation above. 
If the homology between the target polynucleotide and the 40 
sequence to be, detected are not known, the simplest approach 
is to start with both hybridization and wash conditions which 
are nonstringent. If nonspecific bands or high background are 
observed after autoradiography, the filter can be washed at 
high stringency and reexposed. If the time required for expo- 45 
sure makes this approach impractical, several hybridization 
and/or washing stringencies should be tested in parallel. 
Stringent conditions include hybridization in a solution of at 
least about 5xSSC at 65° C., or at leastabout4xSSC at42° C.; 
see, for example, U.S. Pat. No. 5,707,829, the disclosure of 50 
which is herein incorporated by reference. 
Generally, hybridization is performed using at least 18 
contiguous nucleotides of SEQ ID N0:2. That is, when at 
least 18 contiguous nucleotides of SEQ ID N0:2 are used as 
a probe, the probe will preferentially hybridize with a nucleic 55 
acid or mRNA comprising the complementary sequence, 
allowing the identification and retrieval of the nucleic acids of 
the biological material that uniquely hybridize to the selected 
probe. Probes of more than 18 nucleotides can be used, e.g. 
probes of from about 25 nucleotides to about 40 nucleotides, 60 
from about 50 nucleotides to about 72 nucleotides, up to the 
entire coding region can be used, but 18 nucleotides generally 
represents sufficient sequence for unique identification. 
The nucleic acids may also include naturally occurring 
variants of the nucleotide sequences, e.g. degenerate variants, 65 
allelic variants, etc. Variants of the nucleic acids of the inven-
tion are identified, by hybridization of putative variants with 
18 
nucleotide sequences disclosed herein, preferably by hybrid-
ization under stringent conditions. For example, by using 
appropriate wash conditions, variants of the nucleic acids can 
be identified where the allelic variant exhibits at most about 
25-30% base pair mismatches relative to the selected nucleic 
acid probe. In general, allelic variants contain 15-25% base 
pair mismatches, and can Contain as few as even 5-15%, or 
2-5%, or 1-2% base pair mismatches, as well as a single 
base-pair mismatch. 
Another embodiment provides homo logs of GaTxl. Such 
homo logs can be identified by any of a number of methods 
known to those skilled in. the art. A fragment of the provided 
nucleic acid may be used as a hybridization probe against a 
cDNA library front the target organism of interest, where low 
stringency conditions are used. The probe may be a large 
fragment, or one or more short degenerate primers. 
The homo logs corresponding to the nucleic acids encoding 
SEQ ID NO: 1, where, the source ofhomologous genes can be 
any related species, within the same genus or group. Within a 
group, homologs have substantial sequence similarity, e.g. at 
least 75% sequence identity, usually at least 90%, more usu-
ally at least. 95%, preferably 98% or greater between nucle-
otide sequences. Sequence similarity is calculated based on a 
reference sequence, which may be a subset of a larger 
sequence, such as a. conserved motif, coding region, flanking 
region, etc. A reference sequence will usually be at least about 
18 contiguous at long, more usually at least, about 30 nt long, 
and may extend to the complete sequence that is being com-
pared. 
In some embodiments, the polynucleotide includes a 
nucleotide sequence encoding a polypeptide comprising at 
least about 5, 10, 15, 20, 25, 50, 75, 100, 125, or 150 of the 
sequence set forth in SEQ ID NO: 1. In other embodiments, 
the polynucleotide includes a nucleotide sequence encoding 
the entire polypeptide having the amino acid sequence set 
forth in any one of SEQ ID NO: 1. In still other embodiments, 
the polynucleotide includes a nucleotide sequence which 
encodes a polypeptide comprising an amino acid sequence 
sharing, at least about 60%, preferably at least about 70%, 
more preferably at least about 80%, even more preferably at 
least about 87%, 90%, 95%, 98%, or 99% or more amino acid 
sequence identity with the sequence depicted in SEQ ID 
NO:l. 
As is known to one of skill in the art, using the standard 
genetic code table, a polynucleotide encoding a subject 
polypeptide can be designed and using a nucleic acid synthe-
sizer or other means, a polynucleotide encoding a subject 
polypeptide may be produced. 
Various derivatives of an antisense sequence specific for 
SEQ ID N0:2 may be prepared, where the phosphates may be 
modified, where oxygens may be substituted with sulfur and 
nitrogen, the sugars may be modified, and the like. The anti-
sense sequences may be used by themselves or in conjunction 
with various toxic moieties, such as metal chelates, sensitiz-
ers, ribozymes, and the like. Antisense polynucleotides, and 
methods of using such, are described in numerous publica-
tions, including, e.g., "Antisense Technology: A Practical 
Approach" Lichtenstein and Nellen, eds. (1997) IRL Press. 
Antisense molecules specific for GaTxl can be used. to 
down-regulate expression of sGaTxl in cells. The anti-sense 
reagent may be anti sense oligodeoxynucleotides (ODN), par-
ticularly synthetic ODN having chemical modifications from 
native nucleic acids, or nucleic acid constructs that express 
such anti-sense molecules as RNA. The anti sense sequence is 
complementary to the mRNA of the targeted gene, and inhib-
its expression of the targeted gene products. Antisense mol-
ecules inhibit gene expression through various mechanisms, 
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e.g. by, reducing the amount of mRNA available for transla-
tion, through activation ofRNAse H, or steric hindrance. One 
or a combination of antisense molecules may be adminis-




Exemplary siRNAs to GaTXl 
ACA-ACG-GAU-CAU-CAA (SEQ ID 
-CAG-AAG-UGU-GCA-GA (SEQ ID 




Antisense molecules may be produced by expression of all 
or a part of the target gene sequence in an appropriate vector, 
where the transcriptional initiation is oriented such that an 
antisense strand is produced as an RNA molecule. Alterna-
10 tively, the antisense molecule is a synthetic oligonucleotide. 
CAA-UGU-UUG-UGU-AAU (SEQ ID NO, 11) 
Anti sense oligonucleotides will generally be at least about 7, 
usually at least about 12, more usually at least about 20 
nucleotides in length, and not more than about 7 5, usually not 
more than about 50, more usually not more than about 35 
15 
nucleotides in length, where the length is governed by effi-
ciency of inhibition, specificity, including absence of cross-
reactivity, and the like. It has been found that short oligo-
nucleotides, of from 7 to 8 bases in length, can be strong and 
selective inhibitors of gene expression (see Wagner et al. 
20 







(SEQ ID NO, 12) 
(SEQ ID NO, 13) 
(SEQ ID NO, 14) 
(SEQ ID NO, 15) 
(SEQ ID NO, 16) 
(SEQ ID NO, 17) 
A specific region or regions of the endogenous sense strand 
mRNA sequence is chosen to be complemented by the anti-
sense sequence. Selection of a specific sequence for the oli-
gonucleotide may use an empirical method, where several 
25 
candidate sequences are assayed for inhibition of expression 
Another embodiment provides Ga Tx 1 genomic sequences. 
A genomic sequence of interest includes the nucleic acid 
present between the initiation codon and the stop codon, 
including all of the intrans that are normally present in a 
native chromosome. It may further include the 3' and 5' 
of the target gene in an in vitro or animal model. A combina-
tion of sequences may also be used, where several regions of 
the mRNA sequence are selected for antisense complemen-
tation. 
Antisense oligonucleotides may be chemically synthe-
sized by methods known in. the art (see Wagner et al. (1993) 
supra.) Preferred oligonucleotides are chemically modified 
from the native phosphodiester structure, in order to increase 
their intracellular stability and binding affinity. Such modifi-
cations have been previously discussed with respect to the use 
of probes. 
As an alternative to anti-sense inhibitors, catalytic nucleic 
acid compounds, e.g. ribozymes, anti-sense conjugates, 
siRNA, or micro RNA etc. may be used to inhibit gene expres-
sion. Ribozymes may be synthesized in vitro and adminis-
tered, or may be encoded on an expression vector, from which 
the ribozyme is synthesized in targeted cell (for example, see 
International patent application WO 9523225, and Beigel-
man et al. (1995) Nucl. Acids Res 23:4434 42). Examples of 
oligonucleotide with catalytic activity die described in WO 
9506764. Conjugates of anti-sense ODN with a metal com-
plex, e.g. terpyridylCu(II), capable of mediating mRNA 
hydrolysis are described in Bashkin et al. (1995) Appl Bio-
chem Biotechnol 54:43 56. 
untranslated regions found in the mature in mRNA. It may 
further include specific transcriptional and translational regu-
latory sequences, such as promoters, enhancers, etc., includ-
30 ing about 1 kb, but possibly more, up to about 6 kb, of flanking 
genomic DNA at either the 5' or 3' end of the transcribed 
region. The genomic DNA may be isolated as a fragment of 
50 kbp or smaller; and substantially tree of flanking chromo-
somal sequence. The genomic DNA flanking the coding 
35 region, either 3' or 5', or internal regulatory sequences as 
sometimes found-in intrans, contains sequences required for 
proper tissue and stage specific expression. 
The sequence of the 5' flanking region may be utilized for 
promoter elements, including enhancer binding. sites, t~at 
40 provide for regulation in tissues where scorp10n toxms 
polypeptide are expressed. The tissue specific expression is 
useful for determining the pattern of expression, and for pro-
viding promoters that mimic the native pattern of expression. 
Naturally occurring polymorphisms in the promoter region 
45 are useful for determining natural variations in expression. 
Alternatively, mutations may be introduced into the pro-
moter region to determine the effect of altering expression in 
experimentally defined systems. Methods for the identifica-
tion of specific DNA motifs involved in the binding oftran-
50 scriptional factors are known in the art, e.g. sequence simi-
larity to known binding motifs, gel retardation studies, etc. 
For examples, see Blackwell et al. (1995) Mo!. Med, 1:194 
205; Mortlocketal. (1996)GenomeRes. 6:327 33; andJoulin 
One embodiment provides an siRNA specific for mRNA 
encoding GaTxl. Still another embodiment provides a 
microRNA specific for mRNA encoding GaTxl. Still another 
embodiment provides a vector encoding a siRNA or 
microRNA specific for GaTxl mRNA. Exemplary siRNAs 
55 
include but are not limited to those in Table 1 below. One of 
ordina~ skill in the art could readily identify other siRNAs 
using commercially available software and SEQ ID N0:2. 
and Richard-Foy (1995) Eur. J. Biochem, 232:620 626. 
The regulatory sequences may be used to identify cis acting 
sequences required for transcriptional or translational regu-
lation of expression, especially in different tissues or stages of 
development, and to identify cis acting sequences and trans-
acting factors that regulate or mediate expression. Such tran-
TABLE 1 
Exemplary siRNAs to GaTXl 
GGA-GGC-AUU-GGA-AAA (SEQ ID NO, 5) 
U-GGA-CCU-UGC-UUU-A (SEQ ID NO, 6) 
GGA-CCU-UGC-UUU-ACA (SEQ ID NO, 7) 
60 scription or translational control regions may be operably 
linked to one of the subject genes in order to promote expres-
sion of wild type or altered scorpion toxin polypeptide, or 
other proteins of interest in cultured cells. 
The nucleic acid compositions may encode all or a part of 
65 GaTxl. Double or single stranded fragments of the DNA 
sequence may be obtained by chemically synthesizing oligo-
nucleotides in accordance with conventional. methods, by 
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restriction enzyme digestion, by PCR amplification, etc For 
the most part, DNA fragments will be of at least 15 nt, usually 
at least 25 nt or 35 nt or 45 nt but may he as long as 50 nt 60 
nt, 70 nt, 80 nt, and even as long as 90 nt or 100 nt Small DNA 
fragments are useful as primes for PCR, hybridization screen-
ing probes, etc, For use in amplification reactions, such as 
PCR, a pair of primers will, be used. The exact composition of 
the primer sequences is not critical to the invention, but for 
most applications the primers will hybridize to the subject 
sequence under stringent conditions, as known in the art. It is 
preferable to choose a pair of primers that will generate an 
amplification product of at. least about 50 nt, preferably at 
least about 100 nt. Algorithms for the selection of primer 
sequences are generally known, and are available in commer-
cial software packages. Amplification primers hybridize to 
complementary strands of DNA, and will prime towards each 
other. 
The polynucleotides are isolated and obtained in substan-
tial purity, generally as other than an intact chromosome. 
Usually, the DNA will be obtained substantially free of 
nucleic acid sequences other than a scorpion venom toxin-
encoding polynucleotide, generally being at least about 50%, 
usually at least about 90% pure and are typically "recombi-
nant", i.e. flanked by one or more nucleotides with which it is 
not normally associated on a naturally occurring chromo-
some. 
The DNA may also be used to identify expression of the 
gene in a biological specimen. The manner in which one 
probes cells for the presence of particular nucleotide 
sequences, as genomic DNA or RNA, is well established in 
the literature and does not require elaboration here. DNA or 
mRNA is isolated from a cell sample. The mRNA may be 
amplified by RT-PCR, using reverse transcriptase to form a 
complementary DNA strand, followed by polymerase chain 
reaction amplification using primers specific for the subject 
DNA sequences. Alternatively, the mRNA sample is sepa-
rated by gel electrophoresis, transferred to a suitable support, 
e.g. nitrocellulose, nylon, etc., and then probed with a frag-
ment of the subject DNA as a probe. Other techniques, such as 
oligonucleotide ligation assays, in situ hybridizations, and 
hybridization to DNA probes arrayed on a solid chip may also 
find use. Detection of mRNA hybridizing to the subject 
sequence is indicative of scorpion toxin gene expression in 
the sample. 
22 
41 (1993); Sayers et al., Biotechniques 13:592 6 (1992); 
Jones and Winistorfer, Biotechniques 12:528 30 (1992); Bar-
ton et al., Nucleic Acids Res 18:7349 55 (1990); Marotti and 
Tomich, Gene Anal Tech 6:67 70 (1989); and Zhu, Anal 
Biochem 177:120 4 (1989). 
D. GaTxl Homologs 
Homologs and orthologs of scorpion toxin polypeptides, 
for example GaTxl, are identified by any of a number of 
methods. A. fragment of scorpion venom toxin polynucle-
10 otide or cDNA may be used as a hybridization probe against 
a cDNA library from the target organism of interest, where 
low stringency conditions are used. The probe may be a large 
fragment, or one or more short degenerate primers. Nucleic 
acids having sequence similarity are detected by hybridiza-
15 tion under low stringency conditions, for example, at 50° C. 
and 6xSSC (0.9 M sodium chloride/0.09 M sodium citrate) 
and remain bound when subjected to washing at 55° C., in 
lxSSC (0.15 M sodium chloride/0.015 M sodium citrate). 
Sequence identity may be determined by hybridization under 
20 stringent conditions, for example, at 50° C. or higher and 
O.lxSSC (15 mM sodium chloride/01.5 mM sodium citrate). 
Hybridization methods and conditions are welt known in the 
art, see, e.g., U.S. Pat. No. 5,707,829. Nucleic acids having a 
region of substantial identity to a nucleic acid encoding 
25 GaTxl, e.g. allelic variants, genetically altered versions of the 
gene, etc., bind to the GaTxl sequence under stringent 
hybridization conditions. By using probes, particularly 
labeled probes of DNA sequences, one can isolate homolo-
gous or related genes. The source ofhomologous genes can be 
30 any species of scorpion or any other organism that produces 
neurotoxins, e.g., snakes, arachnids, lizards, sea anemones, 
and the like. Between scorpion species, homologs have sub-
stantial sequence similarity, i.e. at least 75% sequence iden-
tity between nucleotide sequences, in some cases 80 or 90% 
35 sequence identity, and may be as high as 95%, 98%, or 99% 
sequence identity between closely related species. Sequence 
similarity is calculated based on a reference sequence, which 
may be a subset of a larger sequence, such as a conserved 
motif, coding region, flanking region, etc. A reference 
40 sequence will usually be at least about 18 nt long, more 
usually at. least about 30 nt long, and may extend to the 
complete sequence that is being compared. Algorithms for 
sequence analysis are known in the art, such as BLAST, 
described inA!tschul et. al. (1990) J. Mo!. Biol. 215:403 10. 
The sequence of a GaTxl-encoding nucleic acid or gene, 45 
including any flanking promoter regions and coding regions, 
may be mutated in various ways known in the art to generate 
targeted changes in promoter strength, sequence of the 
encoded protein, etc. The DNA sequence or protein product 
E. Pharmaceutical Compositions 
Pharmaceutical compositions including an ABC trans-
porter ligand such as GaTxl peptide are provided. Conditions 
alleviated or modulated by the administration of such com-
positions include those indicated below. Such pharmaceutical 
of such a mutation will usually be substantially similar to the 
sequences provided herein, i.e. will differ by at least one 
amino acid, and may differ by at least one or two but not more 
than about ten amino acids. The sequence changes may be 
substitutions, insertions or deletions. Deletions may further 
include larger changes, such as deletions of a domain or exon. 
Other modifications of interest include epitope tagging, e.g. 
with the FLAG system, HA, etc. For studies of subcellular 
localization, fusion proteins with green fluorescent proteins 
(GFP) may be used. 
Techniques for in vitro mutagenesis of clotted genes are 
known. Examples of protocols for site specific mutagenesis 
may be found in Gustin et al., Biotechniques 14:22 (1993); 
Barany, Gene 37: 111 23 (1985); Colicelli et al., Mo! Gen 
Genet 199:537 9 (1985); and Prentki et al., Gene 29:303 13 
(1984). Methods for site specific mutagenesis can be found in 
Sambrook et al., Molecular Cloning: A Laboratory Manual, 
CSH Press 1989, pp. 15.3 15.108; Weiner et al., Gene 126:35 
50 compositions may be for administration by oral, parenteral 
(intramuscular, intraperitoneal, intravenous (IV) or subcuta-
neous injection), transdermal (either passively or using ion-
tophoresis or electroporation), transmucosal (nasal, vaginal, 
rectal, or sublingual) routes of administration or using bio-
55 erodible inserts and can be formulated in dosage forms appro-
priate for each route of administration. In general, pharma-
ceutical compositions are provided including effective 
amounts, of a GaTxl peptide, or derivative products, and 
pharmaceutically acceptable diluents, preservatives, solubi-
60 lizers, emulsifiers, adjuvants and/or carriers. Such composi-
tions include diluents of various buffer content (e.g., Tris-
HCI, acetate, phosphate), pH and ionic strength; additives 
such as detergents and solubilizing agents (e.g., TWEEN 20, 
TWEEN 80, Polysorbate 80), anti-oxidants (e.g., ascorbic 
65 acid, sodium metabisulfite), preservatives (e.g., Thimersol, 
benzyl alcohol) and bulking substances (e.g., lactose, manni-
tol); incorporation of the material into particulate prepara-
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tions of polymeric compounds such as poly lactic acid, polyg-
lycolic acid, etc. or into liposomes. Hyaluronic acid may also 
be used. Such compositions may influence the physical state, 
stability, rate of in vivo release, and rate of in vivo clearance 
of the present proteins and derivatives. See, e.g. Remington's 
Pharmaceutical Sciences, 18th Ed. (1990, Mack publishing 
Co., Eastern. Pa, 18042) pages 1435-1712 which are herein 
incorporated by reference. The compositions may be pre-
pared in liquid form, or may be in dried powder (e.g., lyo-
philized) form. 
1. Oral Delivery 
24 
inert ingredients that are used as enteric coatings are cellulose 
acetate trimellitate (CAT), hydroxypropylmethylcellulose 
phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl 
acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellu-
lose acetate phthalate (CAP), Eudragit L, Eudragit S, and 
Shellac. These coatings may be used as mixed films. 
A coating or mixture of coatings can also be used on 
tablets, which are not intended for protection against the 
stomach. This can include sugar coatings, or coatings which 
10 make the tablet easier to swallow. Capsules may consist of a 
hard shell (such as gelatin) for delivery of dry therapeutic (i.e. 
powder), for liquid forms a soft gelatin shell may be used. The 
shell material of cachets could be thick starch or other edible 
GaTx1 peptide can be formulated for oral delivery. Oral 
solid dosage forms are described generally in Remington's. 
Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing 
Co. Easton Pa. 18042) at Chapter 89, which is herein incor- 15 
porated by reference. Solid dosage forms include tablets, 
capsules, pills, troches or lozenges, cachets, pellets, powders, 
paper. For pills, lozenges, molded tablets or tablet triturates, 
moist massing techniques can be used. 
The peptide (or derivative) can be included in the formu-
lation as fine multiparticulates in the form of granules or 
pellets of particle size about 1 mm. The formulation of the 
material for capsule administration could also be as a powder, 
lightly compressed plugs, or even as tablets. These therapeu-
or granules. Also, liposomal or proteinoid encapsulation may 
be used to formulate the present compositions (as, for 
example, proteinoid microspheres reported in U.S. Pat. No. 20 
4,925,673). Liposomal encapsulation may be used and the 
liposomes may be derivatized with various polymers (e.g., 
U.S. Pat. No. 5,013,556). A description of possible solid 
dosage forms for the therapeutic is given by Marshall, K. In: 
tics could be prepared by compression. 
Colorants and/or flavoring agents may also be included. 
For example, the peptide (or derivative) may be formulated 
(such as by liposome or microsphere encapsulation) and then 
further contained within an edible product, such as a refrig-
Modern Pharmaceutics Edited by G. S. Banker and C. T. 25 
Rhodes Chapter 10, 1979, herein incorporated by reference. 
In general, the formulation will include the ABC transporter 
ligands (or chemically modified forms thereof) and inert 
ingredients which allow for protection against the stomach 
environment, and release of the biologically active material in 30 
the intestine. 
erated beverage containing colorants and flavoring agents. 
One may dilute or increase the volume of the peptide (or 
derivative) with an inert material. These diluents could 
include carbohydrates, especially mannitol, .alpha.-lactose, 
anhydrous lactose, cellulose, sucrose, modified dextrans and 
Another embodiment provides liquid dosage forms for oral 
administration, including pharmaceutically acceptable emul-
sions, solutions, suspensions, and syrups, which may contain 
other components including inert diluents; adjuvants such as 
wetting agents, emulsifying and suspending agents; and 
sweetening, flavoring, and perfuming agents. 
The peptides may be chemically modified so that oral 
delivery of the derivative is efficacious. Generally, the chemi-
cal modification contemplated is the attachment of at least 
one moiety to the component molecule itself, where said 
moiety permits (a) inhibition of proteolysis; and (b) uptake 
into the blood stream from the stomach or intestine. Also 
desired is the increase in overall stability of the component or 
components and increase in circulation time in the body. As 
discussed above, PEGylation is a preferred chemical modifi-
cation for pharmaceutical usage. Other moieties that may be 
used include: propylene glycol, copolymers of ethylene gly-
col and propylene glycol, carboxymethyl cellulose, dextran, 
polyvinyl alcohol, polyvinyl pyrrolidine, polyproline, poly-
1,3-dioxolane and poly-1,3,6-tioxocane [see, e.g., Abu-
chowski and Davis (1981) "Soluble Polymer-Enzyme 
Adducts," in Enzymes as Drugs. Hoeenberg and Roberts, eds. 
(Wiley-Interscience; New York, N.Y.)pp. 367-383; and New-
mark, et al. (1982) J. Appl. Biochem. 4:185-189]. 
For oral formulations, the location of release may be the 
stomach, the small intestine (the duodenum, the jejunem, or 
the ileum), or the large intestine. One skilled in the art has 
available formulations which will not dissolve in the stomach, 
yet will release the material in the duodenum or elsewhere in 
the intestine. Preferably, the release will avoid the deleterious 
effects of the stomach environment, either by protection of 
the peptide (or derivative) or by release of the peptide (or 
derivative) beyond the stomach environment, such as an the 
intestine. 
To ensure full gastric resistance a coating impermeable to 
at least pH 5.0 is essential. Examples of the more common 
starch. Certain inorganic salts may be also be used, as fillers 
including calcium triphosphate, magnesium carbonate and 
sodium chloride. Some commercially available diluents are 
35 Fast-Flo, Emdex, STA-Rx 1500, Emcompress andAvicell. 
Disintegrants may be included in the formulation of the 
therapeutic into a solid dosage form. Materials used as disin-
tegrates include but are not limited to starch, including the 
commercial disintegrant based on starch, Explotab. Sodium 
40 starch glycolate, Amberlite, sodium carboxymethylcellulose, 
ultramylopectin, sodium alginate, gelatin, orange peel, acid 
carboxymethyl cellulose, natural sponge and bentonite may 
all be used. The disintegrants may also be insoluble cationic 
exchange resins. Powdered, gums may be used as disinte-
45 grants and as binders and can include powdered gums such as 
agar, Karaya or tragacanth. Alginic acid and its sodium salt 
are also useful as disintegrants. 
Binders may be used to hold die peptide (or derivative) 
agent together to form a hard tablet and include materials 
50 from natural products such as acacia, tragacanth, starch and 
gelatin. Others include methyl cellulose (MC), ethyl cellulose 
(EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrro-
lidine (PVP) and hydroxypropylmethyl cellulose (HPMC) 
could both be used in alcoholic solutions to granulate the 
55 peptide (or derivative). 
An antifrictional agent may be included in the formulation 
of the peptide (or derivative) to prevent sticking during the 
formulation process. Lubricants may be used as a layer 
between the peptide (or derivative) and the die wall, and these 
60 can include but are not limited to; stearic acid including its 
magnesium and calcium salts, polytetrafluoroethylene 
(PTFE), liquid paraffin, vegetable oils and waxes. Soluble 
lubricants may also be used such as sodium lauryl sulfate, 
magnesium lauryl sulfate, polyethylene glycol of various 
65 molecular weights, Carbowax 4000 and 6000. 
Glidants that might improve the flow properties of the drug 
during formulation and to aid rearrangement during compres-
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sion might be added. The glidants may include starch, talc, 
pyrogenic silica and hydrated silicoaluminate. 
To aid dissolution of the peptide (or derivative) into the 
aqueous environment a surfactant might be added as a wetting 
agent. Surfactants may include anionic detergents such as 
sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dio-
ctyl sodium sulfonate. Cationic detergents might be used and 
could include benzalkonium chloride or benzethomium chlo-
ride. The list of potential nonionic detergents that could be 
included in the formulation as surfactants are lauromacrogoi 
400, polyoxyl 40 stearate, polyoxyethylene hydrogenated 
castor oil 10, 50 and 60, glycerol monostearate, polysorbate 
20, 40, 60, 65 and 80. sucrose fatty acid ester, methyl cellu-
lose and carboxymethyl cellulose. These surfactants could be 
present in the formulation of the protein or derivative either 
alone or as a mixture in different ratios. 
Additives which potentially enhance uptake of the peptide 
(or derivative) are for instance the fatty acids oleic acid, 
linoleic acid and linolenic acid. 
Controlled release oral formulations may be desirable. The 
peptide (or derivative) could be incorporated into an inert 
matrix which permits release by either diffusion or leaching 
mechanisms, e.g., gums. Slowly degenerating matrices may 
also be incorporated into the formulation. Some enteric coat-
ings also have a delayed release effect. Another form of a 
controlled release is by a method based on the Oros therapeu-
tic system (Alza Corp.), i.e. the drug is enclosed in a semi-
permeable membrane which allows water to enter and push 
drug out through a single small opening due to osmotic 
effects. 
Other coatings may be used for the formulation. These 
include a variety of sugars which could be applied in a coating 
pan. The peptide (or derivative) could also be given in a film 
coated tablet and the materials used in this instance are 
divided into 2 groups. The first are the nonenteric materials 
and include methyl cellulose, ethyl cellulose, hydroxyethyl 
cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl 
cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-
methyl cellulose, providone and the polyethylene glycols. 
The second group consists of the enteric materials that are 
commonly esters of phthalic acid. 
A mix of materials might be used to provide the optimum 
film coating. Film coating may be carried out in a pan coater 
or in a fluidized bed or by compression coating. 
2. Parenteral Delivery 
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4. Pulmonary Delivery 
Also contemplated herein is pulmonary delivery of the 
GaTxl peptides for derivatives thereof). The peptide (or 
derivative) is delivered to the kings of a marmnal while inhal-
ing and traverses across the lung epithelial lining to the blood, 
stream [see, e.g., Adjei, et al. (1990) Pharmaceutical 
Research 7:565-569; Adjei, et al. (1990) Int. J, Pharmaceutics 
63; 135-144 (leuproiide acetate); Braquet, et al. (1989) J. 
Cardiovascular Pharmacology 13(sup5): 143-146 ( endothe-
10 lin-1); Hubbard, et al. (1989) Annals of Internal Medicine, 
Vol. III, pp. 206-212 (al-antitrypsin); Smith, et al. (1989) J. 
Clin. Invest. 84:1145-1146 (.alpha.-1-proteinase); Oswein, et 
al. (1990) "Aerosolization of Proteins", Proceedings of Sym-
posium on Respiratory Drug Delivery II Keystone, Colo. 
15 (recombinant human growth hormone); Debs, et al, (1988) J. 
Immunol. 140:3482-3488 (interferon-.garmna, and tumor 
necrosis factor .alpha.); and U.S. Pat. No. 5,284,656 to Platz, 
et al. (granulocyte colony stimulating factor). A method and 
composition for pulmonary delivery of drugs for systemic 
20 effect is described in U.S. Pat. No. 5,451,569 to Wong, et al. 
A wide range of mechanical devices designed for pulmo-
nary delivery of therapeutic products can be used, including 
but not limited to nebulizers, metered dose inhalers, and pow-
derinhalers, all of which are familiar to those skilled in the art. 
25 Some specific examples of commercially available devices 
suitable for the practice of this invention are the Ultravent 
nebulizer (Mailinckrodt Inc., St. Louis, Mo.); the Acorn II 
nebulizer (Marquest Medical Products, Englewood, Colo.); 
the Ventolin metered dose inhaler (Glaxo Inc., Research Tri-
30 angle Park, N.C.); and the Spinhaler powder inhaler (Fisons 
Corp., Bedford, Mass.). 
All such devices require the use of formulations suitable 
for the dispensing of peptide (or derivative). Typically, each 
formulation is specific to the type of device employed and 
35 may involve the use of an appropriate propellant material, in 
addition to the usual diluents, adjuvants and/or carriers useful 
in therapy. Also, the use of liposomes, microcapsules or 
microspheres, inclusion complexes, or other types of carriers 
is contemplated. Chemically modified peptides may also be 
40 prepared in different formulations depending on the type of 
chemical modification or the type of device employed. 
Formulations suitable for use with a nebulizer, either jet or 
ultrasonic, will typically comprise peptide (or derivative) dis-
solved in water at a concentration of about 0.1 to 25 mg of 
45 biologically active protein per mL of solution. The formula-
tion may also include a buffer and a simple sugar (e.g., for 
protein stabilization and regulation of osmotic pressure). The 
nebulizer formulation may also contain a surfactant, to reduce 
or prevent surface induced aggregation of the peptide (or 
Preparations according to this invention for parenteral 
administration include sterile aqueous of non-aqueous solu-
tions, suspensions, or emulsions. Examples of non-aqueous 
solvents or vehicles are propylene glycol, polyethylene gly-
col, vegetable oils, such as olive oil and corn oil, gelatin, and 
injectable organic esters such as ethyl oleate. Such dosage 
forms may also contain adjuvants such as preserving, wetting, 
emulsifying, and dispersing agents. They may be sterilized 55 
by, for example, filtration through a bacteria retaining filter, 
50 derivative) caused by atomization of the solution in forming 
the aerosol. 
Formulations for use with a metered-dose inhaler device 
will generally include a finely divided powder containing the 
peptide (or derivative) suspended in a propellant with the aid 
of a surfactant. The propellant may be any conventional mate-
rial employed for this purpose, such as a chlorofluorocarbon, 
a hydrochlorofluorocarbon, a hydro fluorocarbon, or a hydro-
carbon, including trichlorofluoromethane, dichlorodifluo-
romethane, dichlorotetrafluoroethanol, and 1, 1, l ,2-tetrat-
by incorporating sterilizing agents into the compositions, by 
irradiating the compositions, or by beating the compositions. 
They can also be manufactured using sterile water, or some 
other sterile injectable medium, immediately before use. 
3. Rectal or Vaginal Delivery 
60 fluoroethane, or combinations thereof. Suitable surfactants 
include sorbitan trioleate and soya lecithin. Oleic acid may 
also be useful as a surfactant. Compositions for rectal or vaginal administration are pref-
erably suppositories which may contain, in addition to the 
active substance, excipients such as cocoa butter or a supposi-
tory wax. Compositions for nasal or sublingual administra- 65 
ti on are also prepared with standard excipients well known in 
the art. 
Formulations for dispensing from a powder inhaler device 
will include a finely divided dry powder containing peptide 
(or derivative) and may also include a bulking agent, such as 
lactose, sorbitol, sucrose, or mannitol in amounts which 
facilitate dispersal of the powder from the device, e.g., 50 to 
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90% by weight of the formulation. The peptide (or derivative) 
should most advantageously be prepared in particulate form 
with an average particle size ofless than 10 mm (or microns), 
most preferably 0.5 to 5 mm, for most effective delivery to the 
distal lung. 
5. Nasal Delivery 
Nasal of the ABC transporter ligand (or derivatives) is also 
contemplated. Nasal delivery allows the passage of the pep-
tide to the blood stream directly after administering the thera-
peutic product to the nose, without the necessity for deposi-
tion of the product in the lung. Formulations for nasal delivery 
include those with dextran or cyclodextran. 
Other penetration-enhancers used to facilitate nasal deliv-
ery are also contemplated for use with the peptides of the 
present invention (such as described in International Patent 
Publication No. WO 2004056314, filed Dec. 17, 2003, incor-
porated herein by reference in its entirety). 
6. Dosages 
For all of the peptide compounds, as further studies are 
conducted, information will emerge regarding appropriate 
dosage levels for treatment of various conditions in various 
patients, and the ordinary skilled worker, considering the 
therapeutic context, age, and general health of the recipient, 
will be able to ascertain proper dosing. The selected dosage 
depends upon the desired therapeutic effect, on the route of 
administration, and on the duration of the treatment desired. 
Generally dosage levels of0.001 to 10 mg/kg of body weight 
daily are administered to mammals. Generally, for intrave-
nous injection or infusion, dosage may be lower. 
7. Polymeric Matrices 
Both non-biodegradable and biodegradable matrices can 
be used for delivery of ABC transporter ligands such as 
GaTxl peptides, although biodegradable matrices are pre-
ferred. These may be natural or synthetic polymers, although 
synthetic polymers are preferred due to the better character-
ization of degradation and release profiles. The polymer is 
selected based on the period over which release is desired. In 
some cases linear release, may be most useful, although in 
others a pulse release or "bulk release" may provided more 
effective results. The polymer may be in the form of a hydro-
gel (typically in absorbing up to about 90% by weight of 
water), and can optionally be crosslinked with multivalent 
ions or polymers. 
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Examples of non-biodegradable polymers include ethyl-
ene vinyl acetate, poly(meth)acrylic acid, polyamides, 
copolymers and mixtures thereof. Examples of biodegrad-
able polymers include synthetic polymers such as polymers 
5 of lactic acid and glycolic acid, polyanhydrides, poly( ortho) 
esters, polyurethanes, poly(butic acid), poly(valeric acid), 
and poly(lactide-co-caprolactone ), and natural polymers 
such as alginate and other polysaccharides including dextran 
and cellulose, collagen, chemical derivatives thereof (substi-
lO tutions, additions of chemical groups, for example, alkyl, 
alkylene, hydroxylations, oxidations, and other modifications 
routinely made by those skilled in the art), albumin and other 
hydrophilic proteins, zein and other prolamines and hydro-
15 phobic proteins, copolymers and mixtures thereof. In general, 
these materials degrade either by enzymatic hydrolysis or 
exposure to water in vivo, by surface or bulk erosion. 
Bioadhesive polymers of particular interest include bio-
erodible hydrogels described by H. S. Sawhney, C. P. Pathak 
20 and J. A. Hubell in Macromolecules, 1993, 26, 581-587, 
polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, 
polyacrylic acid, alginate, chitosan, poly(methyl methacry-
lates ), poly( ethyl methacrylates), poly(butylmethacrylate ), 
poly (isobutyl methacrylate ), poly(hexylmethacrylate ), poly 
25 (isodecyl methacrylate ), poly(lauryl methacrylate ), poly 
(phenyl methacrylate ), poly( methyl acrylate), poly(isopropyl 
acrylate), poly(isobutyl acrylate), and poly( octadecyl acry-
late). 
The matrix can be in the form of microparticles such as 
30 microspheres, where peptides are dispersed within a solid 
polymeric matrix or microcapsules, where the core is of a 
different material than the polymeric shell, and the peptide is 
dispersed or suspended in the core, which may be liquid or 
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solid in nature. Unless specifically defined herein, micropar-
ticles, microspheres, and microcapsules are used inter-
changeably. Alternatively, the polymer may be cast as a thin 
slab or film, ranging from nanometers to four centimeters, a 
powder produced by grinding or other standard techniques, or 
40 even a gel such as a hydrogel. 
The matrices can be formed by solvent evaporation, spray 
drying, solvent extraction and other methods known to those 
skilled in the art. 
Representative synthetic polymers that can be used for 45 
delivery include polyamides, polycarbonates, polyalkylenes, 
polyalkylene glycols, polyalkylene oxides, polyalkylene 
terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl 
esters, polyvinyl halides, polyvinylpyrrolidone., polygly-
colides, polysiloxanes, polyurethanes and co-polymers 50 
thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose 
ethers, cellulose esters, nitro celluloses, polymers of acrylic 
and methacrylic esters, methyl cellulose, ethyl cellulose, 
hydroxy propyl cellulose, hydroxy-propyl methyl cellulose, 
hydroxybutyl methyl cellulose, cellulose acetate, cellulose 55 
propionate, cellulose acetate butyrate, cellulose acetate 
phthalate, carboxylethyl cellulose, cellulose triacetate, cellu-
lose sulphate sodium salt, poly(methyl methacrylate), poly 
(ethyl methacrylate ), poly(butylmethacrylate ), poly(isobutyl 
Bioerodible microspheres can be prepared using any of the 
methods developed for making microspheres for drug deliv-
ery, for example, as described by Mathiowitz and Langer, J. 
Controlled Release 5, 13-22 (1987); Mathiowitz, et al., Reac-
tive Polymers 6, 275-283 (1987); and Mathiowitz, et al., J. 
Appl. Polymer Sci, 35, 755-774 (1988). The selection of the 
method depends on the polymer selection, the size, external 
morphology, and crystallinity that is desired, as described, for 
example, by Mathiowitz, et al. Scanning Microscopy 4, 329-
340 (1990); Mathiowitz, et al., J. Appl. Polymer Sci. 45, 
125-134 (1992); and Benita, et al., J. Phann. Sci, 73, 1721-
1724 (1984 ). In solvent evaporation, described for example, 
in Mathiowitz, et al., (1990), Benita, and U.S. Pat. No. 4,272, 
398 to Jaffe, the polymer is dissolved in a volatile organic 
solvent. The peptide either in soluble form or dispersed as fine 
particles, is added to the polymer solution, and the mixture is 
suspended in an aqueous phase that contains a surface active 
agent such as poly(vinyl alcohol). The resulting emulsion is 
methacrylate ), poly(hexylmethacrylate ), poly(isodecyl 60 
methacrylate ), poly(lauryl methacrylate ), poly(phenyl meth-
acrylate ), poly( methyl acrylate), poly(isopropyl acrylate), 
poly(isobutyl acrylate), poly( octadecyl acrylate), polyethyl-
ene, polypropylene, poly( ethylene glycol), poly( ethylene 
oxide), poly( ethylene terephthalate ), poly( vinyl alcohols), 65 
polyvinyl acetate, poly vinyl chloride, polystyrene add poly-
vinylpyrrolidone. 
stirred until most of the organic solvent evaporates, leaving 
solid microspheres. In general, the polymer can be dissolved 
in methylene chloride. Microspheres with different sizes 
(1-1000 microns) and morphologies can be obtained by this 
method which is useful for relatively stable polymers such as 
polyesters and polystyrene. However, labile polymers such as 
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polyanhydrides may degrade due to exposure to water. For 
these polymers, hot melt encapsulation and solvent removal 
may be preferred. 
In hot melt encapsulation, the polymer is first melted and 
then mixed with the solid particles of peptides. The mixture is 
suspended in a non-miscible solvent such as silicon oil and, 
with continuous stirring, heated to 5° C. above the melting 
point of the polymer. Once the emulsion is stabilized, it is 
cooled until the polymer particles solidify. The resulting 
microspheres are washed by decantation with petroleum 10 
ether to give a free-flowing powder. Micro spheres with diam-
eters between one and 1000 microns can be obtained with this 
method. The external surface of spheres prepared with this 
technique are usually smooth and dense. This procedure is 
15 
useful with water labile polymers, but is limited to use with 
polymers with molecular weights between 1000 and 50000. 
Solvent removal was primarily designed for use with polyan-
hydrides. In this method, the drug is dispersed or dissolved in 
a solution of a selected polymer in a volatile organic solvent 20 
like methylene chloride. The mixture is then suspended in oil, 
such as silicon oil, by stirring, to form an emulsion. Within 24 
hours, the solvent diffuses into the oil phase and the emulsion 
droplets harden into solid polymer microspheres. Unlike sol-
vent evaporation, this method can be used to malic micro- 25 
spheres from polymers with high melting points and a wide 
range of molecular weights. Microspheres having a diameter 
between one and 300 microns can be obtained with this pro-
cedure. The external morphology of the spheres is highly 
dependent on the type of polymer used. In spray drying, the 30 
polymer is dissolved in methylene chloride (0.04 g/ml), A 
known amount of active drug is suspended (if insoluble) or 
co-dissolved (if soluble) in the polymer solution. The solution 
or the dispersion is then spray-dried. Double walled micro-
35 
spheres can be prepared according to U.S. Pat. No. 4,861,627 
to Mathiowitz. 
Hydro gel micro spheres made of gel-type polymers such as 
alginate or polyphosphates or other dicarboxylic polymers 
can be prepared by dissolving the polymer in an aqueous 40 
solution, suspending the material to be incorporated into the 
mixture, and extruding the polymer mixture through a micro-
droplet forming device, equipped with a nitrogen gas jet. The 
resulting microspheres fall into a slowly stirring, ionic hard-
ening bath, as described, for example, by Salib, et al., Phar- 45 
mazeutische Industrie 40-1 lA, 1230 (1978). Chitosan micro-
spheres can be prepared by dissolving the polymer in acidic 
solution and crosslinking with tripolyphosphate. For 
example, carboxymethylcellulose (CMC) microsphere are. 
prepared by dissolving the polymer in an acid solution and 50 
precipitating the microspheres with lead ions. Alginate/poly-
ethylene imide (PEI) can be prepared to reduce the amount of 
carboxyl groups on the alginate microcapsules. 
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protein, then appending the DNA sequence of the second 
protein in frame. That DNA sequence will then be expressed 
by a cell as a single protein. 
In one embodiment a linker (or "spacer") peptides are also 
added which make it more likely that the proteins fold inde-
pendently and behave as expected. Especially in the case 
where the linkers enable protein purification, linkers in pro-
tein or peptide fusions can be engineered with cleavage sites 
for proteases or chemical agents which enable the liberation 
of the two separate proteins. 
The disclosed fusion proteins are useful for identification 
and purification ofGaTxl, by fusing a GST protein, FLAG 
peptide, or a hexa-his peptide (a 6xhis-tag) which can be 
isolated using nickel or cobalt resins (affinity chromatogra-
phy). 
in one embodiment GaTxl or derivative thereof can be 
fused to a cytotoxic moiety such as ricin, saporin, or pseud-
onomas exotoxin. Such fusion proteins can be useful for 
delivering cytotoxic materials to cells with chloride channels. 
In another embodiment GaTxl peptide can be labeled with 
a radioisotope. For example I 125 , fluorophore, or other detect-
able agent. Labeled GaTxl can be useful for detecting chlo-
ride channels in a biological sample, in particular for detect-
ing CFTR, or for the selective ablation of cells over-
producing CFTR. 
Still another embodiment provides an ABC transporter 
ligand fused to protein transduction domain, localization sig-
nal or both. Protein transduction domains include but are not 
limited to HIV TATYGRKKRRQRRR (SEQ. ID NO. 3) or 
RKKRRQRRR (SEQ. ID NO. 4); 11 Arginine residues, or 
positively charged polypeptides or polynucleotides having 
8-15. residues, preferably 9-11 residues, Antp SGRQIKIW-
FQN-RRMKWKKC (SEQ ID N0:18), and HIV Tat 
SGYGRKKRRQRRRC (SEQ ID NO: 19). 
The ABC transporter ligand can be operably linked to an 
antibody or antigen-binding fragment of the antibody so that 
the ABC transporter ligand can be selectively delivered to a 
target expressing an epitope recognized by the antibody. The 
antibody can be a single chain antibody, monoclonal anti-
body, polyclonal antibody, humanized antibody, or chimeric 
antibody. 
III. Methods of Manufacture 
A. Purification 
A bioassay-guided fractionation of Lqh venom may be 
used to isolate a peptide ligand that interacts with ABC trans-
porters, for example CFTR ion channels. The fractionation 
approach may include, for example, the following steps: 
homogenization to disrupt mucus contained in the venom, 
recovery of components below 10 kDa molecular weight by 
separation through a centrifuge filter resulting in "Lqh-pf 
venom", testing for activity against the ion channel expressed 
inXenopus oocytes, using recordings from inside-out single-
channel patches or macropatches, initial fractionation 
according to hydrophobicity by reversed-phase HPLC(RP-
HPLC) in a gradient of acetonitrile in water, testing fractions 
for activity against CFTR expressed in Xenopus oocytes, 
using recordings from inside-out single-channel patches or 
Other delivery systems including films, coatings, pellets, 
slabs, and devices can be fabricated using solvent or melt 55 
casting, and extrusion, as well as standard methods for mak-
ing composites. The polymer can be produced by first mixing 
monomers and peptides as described by Sawhney, et al., and 
polymerizing the monomers with UV light. The polymeriza-
tion can be carried out in vitro as well as in vivo. 60 macropatches, secondary fractionation according to molecu-
lar weight by size-exclusion using gel filtration chromatog-
raphy, desalting of fractions using RP-HPLC, with collection 
of individual chromatographic peaks, testing for activity 
against the ion channel expressed in Xenopus oocytes, using 
F. Fusion Proteins 
Another embodiment provides a fusion protein including 
GaTXl or a biologically active fragment thereof is fused to a 
heterologous peptide or protein. A fusion protein is a protein 
created through genetic engineering from two or more pro-
teins/peptides. This is achieved by creating a fusion gene: 
removing the stop codon from the DNA sequence of the first 
65 recordings from inside-out single-channel patches and/or 
macropatches, characterization of material represented in 
individual chromatographic peak using MALDI-TOF, and 
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breaking of the disulfide bridges in the isolated toxin by 
reduction and subsequent carboxymethylation of free cys-
teines. The primary sequence may be determined using 
Edman degradation, but any known method of amino acid 
sequences may be used. 
B. Synthesis of ABC Transport Ligands 
Certain embodiments provide peptides that selectively 
bind to ABC transporters including anion channels and 
inhibit the transport anions through the channel. These pep-
tide ligands of anion channels can be synthesized using gen-
eral methods, for peptide synthesis and purification, and dis-
ulfide bond formation, known in the art. As described in the 
Examples, linear peptides, were produced by solid phase 
synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) chem-
istry. Coupling ofFmoc amino acids was performed using the 
HBTU/HOBT/DIPEA method on an Applied Biosystems 
43 lA synthesizer. The purified linear peptide was subjected 
to oxidative cyclization under equilibrating conditions in 
order to promote formation of the most stable disulfide 
bridges, with the reaction being monitored by analytical 
HPLC. Cyclized peptide was isolated from the acidified reac-
tion mixture by reversed phase extraction, was purified by 
HPLC, and was characterized by MALDI-MS for molecular 
weight determination (FIG. 8) and by analytical HPLC (FIG. 
9) for comparison with the native toxin. 
Another embodiment provides polypeptides having 80%, 
85%, 90%, 95%. or 98% sequence identity or greater to SEQ 
ID NO: 1, preferably having 99% sequence identity or greater 
to SEQ ID NO: 1 optionally where one or more amino acids 
are modified, such as by incorporation of biotin, or are sub-
stituted by non-natural amino acids. 
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predominant inflammatory bowel syndrome, secretory diar-
rhea, and in autosomal dominant polycystic kidney disease 
(ADPKD). 
Another embodiment provides a method of treating a dis-
order or a symptom of disorder selected from the group con-
sisting of cancer, cystic fibrosis, epilepsy, renal tubular dis-
orders, Barrier's syndrome, Dent's disease, myotonia, 
steopetrosis, Angleman or Prader-Willi, upregulation of chlo-
ride channels in glioma cells, diarrhea-predominant inflam-
10 matory bowel syndrome, autosomal dominant polycystic kid-
ney disease (AD PKD ), secretory diarrhea by administering to 
a host inneed thereof an effective amount ofGaTxl, a variant, 
derivative, or a prodrug thereof. 
The roost common genotype among cystic fibrosis (CF) 
15 patients in this country, by far, is the llF508 mutation, which 
leads to the deletion (fl) of the phenylalanine at position 508. 
This single genotype (one of> 1500 mutations known in the 
CFTR gene) is found on at least one chromosome in some 
67% of CF patients in this country. CFTR proteins bearing the 
20 llF508 mutation are recognized as misfolded during the pro-
tein processing pathway that every newly-made protein fol-
lows. Chaperone proteins interact with this part of the CFTR 
protein (and others), and sense that it is misshaped in the 
llF508-CFTR. When this happens, processing along the pro-
25 ductive pathway stops, and the new protein is degraded. 
Because the affinity of GaTxl for CFTR is higher than the 
affinity of the chaperone proteins for CFTR, Ga Tx 1 can com-
pete with chaperone proteins for binding sites on CFTR and 
thereby prevent or reduce the binding of chaperone proteins 
30 to CFTR allowing the protein to continue through the pro-
cessing pathway. Hence, GaTxl may overcome the traffick-
ing defect associated with llF508-CFTR. Synthetic peptides representing portions of the instant 
amino acid sequences may be synthesized by solid-phase 
chemistry. Alternatively, toxin peptides may be produced by 
recombinant methods upon expression in prokaryotic or 
eukaryotic cells. These peptides can be used to immunize 
animals to produce polyclonal or monoclonal antibodies with 
specificity for peptides or proteins comprising the amino acid 
sequences. These antibodies can be then be used to screen 
cDNA expression libraries to isolate full-length cDNA clones 40 
ofinterest (Lerner (1984)Adv. Immunol. 36:1-34; Maniatis). 
Thus, another embodiment provides a method of reducing 
chaperone protein interaction with CFTR by contacting the 
35 CFTR with an ABC transporter ligand such as GaTxl. 
Yet another embodiment provides a method for reducing 
ABC transporter activity by contacting die ABC transporter 
with a ligand having at least 80% sequence identity to SEQ ID 
NO:l. 
Another embodiment provides a method for reducing chlo-
ride channel function by contacting the chloride channel with 
a GaTxl peptide, variant, derivative or prodrug thereof. 
IV. Methods of Using ABC Transporter Ligands Still another embodiment provides a method for treating a 
disorder or symptom of a disorder related to an overactive 
A. Methods of Treatment 
Diseases, disorders, or symptoms of disease or disorders 
related to aberrant ABC transporter activity can be treated 
using the disclosed ABC transporter ligands. For example, 
diseases associated with defective or overactive ion channels, 
45 chloride channel including administering a pharmaceutical 
composition including an effective amount of GaTxl, a 
derivative, variant or prodrug thereof. The administration of a 
peptide ligand obtained from scorpion venom is believed to 
act to lock closed chloride channels, for example CFTR, and 
50 thereby reduce chloride ion transport through chloride chan-
nels. 
in particular chloride channels can be treated using the dis-
closed peptides and peptide compositions. One embodiment 
provides a method of treating a subject by administering to 
the subject an effective amount of the pharmaceutical com-
position including a therapeutically effective amount of a 
ABC transporter ligand, for example GaTxl, a variant or a 55 
pharmaceutically acceptable salt or solvate thereof. By "phar-
maceutically acceptable salts" is meant any salts that are 
known or later discovered to be pharmaceutically acceptable. 
Some examples are: acetate; trifluoroacetate; hydrohalides, 
such as hydrochloride and hydrobromide; sulfate; citrate; 60 
maleate; tartrate; glycolate; gluconate; succinate; mesylate; 
besylate; and oxalate salts. Some diseases attributed to defec-
tive, aberrant or overactive ion channels, in particular over-
active chloride ion channels includes cancer, cystic fibrosis, 
epilepsy, renal tubular disorders. Bartter's syndrome, Dent's 65 
disease, myotonia, osteopetrosis, Angleman or Prader-Willi, 
upregulation of chloride channels k glioma cells, diarrhea-
Another embodiment provides a method for reducing chlo-
ride ion transport through CFTR by contacting CFTR with a 
peptide ligand or biologically active fragment thereofisolated 
from scorpion venom. The scorpion venom peptide ligand 
can be GaTxl or a biologically active fragment thereof. 
Another embodiment provides a method of inhibiting an 
ABC transporter or a domain thereofCFTR by contacting the 
ABC transporter with GaTxl, a variant thereof a derivative 
thereof, or a biologically active fragment thereof. 
ABC transporters include polypeptides encoded by the 
following genes; ABCAl, ABCA2, ABCA3, ABCA4, 
AABCA5, ABCA6, ABCA7, ABCA8, ABCA9, ABCAlO, 
ABCA12, ABCA13, ABCBl, ABCB2, ABCB3, ABCB4, 
ABCB5, ABCB6, ABCB7, ABCB8, ABCB9, ABCBlO, 
ABCBll, ABCCl, ABCC2, ABCC3, ABCC4, ABCC5, 
ABCC6, CFTR, ABCC8, ABCC9, ABCClO, ABCCll, 
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ABCC12, ABCDl, ABCD2, ABCD4, ABCEl, ABCFl, 
ABCF2,ABCF3,ABCG1,ABCG2,ABCG4, andABCG5. In 
one embodiment the GaTxl is ligand for one or more ABC 
transporters. 
B. Detection Methods 
Various embodiments provide a variety of detection meth-
ods, which methods are useful in diagnostic assays. Also 
provided are a variety of screening assays, which assays are 
useful for identifying agents which affect ABC transporter 
ligand activity (e.g., ion channel binding) and/or ABC trans-
porter ligand mRNA and/or polypeptide levels. 
Detection methods include methods for detecting ABC trans-
porter ligands in a biological sample, methods for detecting 
ABC transporter ligand mRNA in a biological sample, and 
methods for detecting ABC transporter ligand-ion channel 
binding in a biological sample. 
1. Methods of Detecting GaTxl in a Biological Sample 
Other embodiments provide methods for detecting the 
presence and/or measuring a level of an ABC transporter 
ligand, for example GaTxl, in a biological sample, using a 
ABC transporter ligand-specific antibody. The methods gen-
erally include: 
a) contacting the sample with an antibody specific for 
GaTxl; and 
b) detecting binding between the antibody and molecules 
of the sample. 
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a) contacting the sample with an ABC transporter, for 
example CFTR protein or fragment thereof; and 
b) detecting binding between the ABC transporter and 
molecules of the sample. 
Detection of specific binding of the ABC transporter is an 
indication that GaTxl polypeptides are present in the sample. 
Methods for detecting binding between a ABC transporter 
ligand and an ABC transporter are known in the art and 
include immunoprecipitation of ABC transporter-ligand 
10 complexes using an antibody specific to the ABC transporter 
ligand or ABC transporter, as long as the antibody does not 
disrupt s ABC transporter ligand -ABC transporter binding. 
Alternatively, the ion channel polypeptide used may be a 
fusion protein which provides for specific immunoprecipita-
15 tion of the fusion partner, an enzymatic detection, a fluores-
cent signal (e.g., a green fluorescent protein). The ion chan-
nel, polypeptide can be labeled with any detectable label, as 
described below. The ion channel polypeptide can be 
attached, directly or through a linker, to an insoluble support 
20 (e.g., polystyrene beads, magnetic beads, and the like), 
thereby providing a means for separating scorpion toxin fam-
ily polypeptide-ion channel/receptor complexes from the bio-
logical sample, and subsequently detecting the presence of 
and/or measuring the amount (level) of scorpion venom toxin 
25 polypeptide. 
Binding of ABC transporter ligand to the ion channel may 
also be detected by monitoring ion channel activity, using 
methods such as electrophysiology (two electrode voltage 
clamp or single electrode patch clamp), guanidinium ion flux 
30 assays, toxin-binding assays, and Fluorometric Imaging Plate 
Reader (FLIPR) assays. (See, e.g., Sullivan, et al. (1999) 
Methods Mo!. Biol. 114:125 133; Siegel and Isacoff (1997) 
Neuron 19:1 20; andLopatin, et al. (1998) Trends Pharmacol. 
Detection of specific binding of the GaTxl-specific anti-
body, when compared to a suitable control, is an indication 
that ABC transporter ligands are present in the sample. Suit-
able controls include a sample known not to contain a ABC 
transporter ligand (GaTxl); and a sample contacted with an 
antibody not specific for a s ABC transporter ligand, e.g., an 
anti-idiotype antibody. A variety of methods to detect specific 
antibody-antigen interactions are known in the art and can be 
used in the method, including, but not limited to, standard 35 
immunohistological methods, immunoprec1p1tation, an 
enzyme immunoassay, and a radioimmunoassay. In general, 
the scorpion venom toxin polypeptide-specific antibody will 
Sci. 19:395 398.) 
2. Methods of Detecting GaTxl mRNA in a Biological 
Sample 
One embodiment provides methods for detecting the pres-
ence of ABC transporter ligandmRNA ina biological sample. 
The methods can be used, for example, to assess whether a 
40 test compound affects ABC transporter ligand gene expres-
sion, directly or indirectly. 
be detectably labeled, either directly or indirectly. Direct 
labels include radioisotopes; enzymes whose products are 
delectable (e.g., luciferase, ~-galactosidase, and the like); 
fluorescent labels (e.g., fluorescein isothiocyanate, 
rhodamine, phycoerythrin, and the like); fluorescence emit-
ting metals, e.g., 152Eu, or others of the lanthanide series, 
attached to the antibody through metal chelating groups such 
as EDTA; chemiluminescent compounds, e.g., luminol, iso-
luminol, acridinium salts, and the like; bioluminescent com-
pounds, e.g., luciferin, aequorin (green fluorescent protein), 
and the like. The antibody may be attached (coupled) to an 
insoluble support, such as a polystyrene plate or a bead. 
Indirect labels include second antibodies specific for scorpion 
venom toxin polypeptide-specific antibodies, wherein the 
second antibody is labeled as described above; and members 
of specific binding pairs, e.g., biotin-avidin, and the like. The 
biological sample may be brought into contact with and 
immobilized on a solid support or carrier, such as nitrocellu-
lose, that is capable of immobilizing cells, cell particles, or 
soluble proteins. The support may then be washed with suit-
able buffers, followed by contacting with a detectably-labeled 
scorpion venom toxin polypeptide-specific antibody. Detec-
tion methods are known in the art and will be chosen as 
appropriate to the signal emitted by the detectable label. 
Detection is generally accomplished in comparison to suit-
able controls, and to appropriate standards. 
An exemplary method generally includes: 
a) contacting the sample with a ABC transporter ligand-
encoding polynucleotide under conditions which allow 
45 hybridization; and 
b) detecting hybridization, if any. 
Detection of hybridization, when compared to a suitable 
control, is an indication of the presence in the sample of a 
ABC transporter ligand-encoding polynucleotide, for 
50 example a GaTxl-encoding polynucleotide. Appropriate 
controls include, for example, a sample which is known not to 
contain s ABC transporter ligand -encoding polypeptide 
mRNA, and use of a labeled polynucleotide of the same 
"sense" as a ABC transporter ligand mRNA. Conditions 
55 which allow hybridization are known in the art, arid have been 
described in more detail above. Detection can be accom-
plished by any known method, including, but not limited to in 
situ hybridization, PCR, RT-PCR, and "Northern" or RNA 
blotting, or combinations of such techniques, using a suitably 
60 labeled ABC transporter ligand polynucleotide, A variety of 
labels and labeling methods for polynucleotides are known in 
the art and can be used in the assay methods of the invention. 
Specific hybridization can be determined by comparison to 
appropriate controls. 
Still other embodiments provide methods for detecting the 65 
presence and/or measuring a level of GaTxl in a biological 
sample. The methods generally comprise: 
Methods using PCR amplification can be performed on die 
DNA from a single cell, although it is convenient to use at 
least about 105 cells. The use of the polymerase chain reac-
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date agents may be small organic compounds having a 
molecular weight of more than 50 and less than about 2,500 
daltons. Candidate agents may comprise functional groups 
necessary for structural interaction with proteins, particularly 
hydrogen bonding, and typically include at least an amine, 
carbonyl, hydroxyl or carboxyl group, and may contain at 
least two of the functional chemical groups. The candidate 
agents may comprise cyclical carbon or heterocyclic struc-
tures and/or aromatic or polyaromatic structures substituted, 
with one or more of the above functional groups. Candidate 
agents are also found among biomolecules including pep-
tides, saccharides, fatty acids, steroids, purines, pyrimidines, 
derivatives, structural analogs or combinations thereof. 
Candidate agents are obtained from a wide variety of 
sources including libraries of synthetic or natural com-
pounds. For example, numerous means are available for ran-
dom and directed synthesis of a wide variety of organic com-
pounds and biomolecules, including expression of 
tion is described in Saiki et al. (1985) Science 239:487, and a 
review of current techniques may be found in Sambrook, et al. 
Molecular Cloning: A Laboratory Manual, CSH Press 1989, 
pp. 14.2B14.33. A detectable label may he included in the 
amplification reaction. Suitable labels include fluoro-
chromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, 
Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluo-
rescein (6-FAM), 2',7'-dimethoxy-4=,5=-dichloro-6-car-
boxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 
-6-carboxy-2' ,4', 7' ,4, 7-hexachlorofluorescein (HEX), 5-car- 10 
boxyfluorescein (5-FAM) or N,N,N=,N=tetramethyl-6-car-
boxyrhodamine (TAMRA). radioactive labels, e.g. 32P, 35S, 
3H; etc. The label may be a two stage system, where the 
amplified DNA is conjugated to biotin, haptens, etc. having a 
high affinity binding partner, e.g. avidin, specific antibodies, 15 
etc., where the binding partner is conjugated to a detectable 
label. The label may be conjugated to one or both of the 
primers. Alternatively, the pool of nucleotides used in the 
amplification is labeled, so as to incorporate the label into the 
amplification product. 20 randomized oligonucleotides and oligopeptides. Alterna-
tively, libraries of natural compounds in the form of bacterial, 
fungal, plant and animal extracts are available or readily 
produced. Additionally, natural or synthetically produced 
libraries and compounds are readily modified through con-
C. Research Tools 
The disclosed peptide ABC transporter ligands can be used 
to investigate ABC transporter structure and function. For 
example, GaTxl can be used as a structural probe of the 
CFTR protein or its domains, or any other member of the 
ABC transporter superfamily, or their domains. For example, 
GaTxl, or a derivative of GaTxl, can be used to stabilize the 
conformation of CFTR protein, or its domains, or any other 
member of the ABC transporter superfamily, or their 
domains, in crystallization experiments. 
Additionally, GaTxl, or a derivative ofGaTxl, can be used 
to isolate CFTR, or its domains, or any other member of the 
ABC transporter superfamily, or their domains, by way of 
affinity chromatography wherein GaTxl, or a derivative of 
GaTxl, is coupled to a solid support. 
V. Screening Assays 
Another embodiment provides screening methods for 
identifying agents which modulates ABC transporter ligand-
ABC transporter binding activity such as GaTxl-ABC trans-
porter binding activity, methods for identifying agents which 
GaTxl-ABC transporter interaction, methods for identifying 
agents which modulate a level of GaTxl in a cell, and meth-
ods for identifying agents which -modulate a level of GaTxl 
mRNA in a cell. 
As used herein, the terra "modulate" encompasses 
"increase" and "decrease". Of particular interest are agents 
which modulate GaTxl-ABC transporter binding activity, 
and/or which modulate GaTxl-ion channel interaction, and/ 
or which modulate a level of ABC transporter ligand in a cell, 
and/or which modulate a level of GaTxl mRNA in a cell. 
Such agents are of interest as candidates for treating diseases 
25 ventional chemical, physical and biochemical means, and 
may be used to produce combinatorial libraries. Known phar-
macological agents may be subjected to directed or random 
chemical modifications, such as acylation, alkylation, esteri-
fication, amidification, etc. to produce structural analogs. 
30 Furthermore, pharmacophores may be designed based on the 
structural aspects of the ion channel/receptor binding inter-
faces of scorpion venom toxin polypeptides. 
Where the screening assay is a binding assay, one or more 
of the molecules may be joined to a label where the label can 
35 directly or indirectly provide a detectable signal. Various 
labels include radioisotopes, fluorescers, chemiluminescers, 
enzymes, specific binding molecules, particles, e.g. magnetic 
particles, and the like. Specific binding molecules include 
pairs, such as biotin and streptavidin, digoxin and antidigoxin 
40 etc. For the specific binding members, the complementary 
member would normally be labeled with a molecule that 
provides for detection, in accordance with known procedures. 
A variety of other reagents may be included in the screen-
ing assay. These include reagents like salts, neutral proteins, 
45 e.g. albumin, detergents, etc that are used to facilitate optimal 
protein-protein binding, and/or reduce non-specific or back-
ground interactions. Reagents that improve the efficiency of 
the assay, such as protease inhibitors, nuclease inhibitors, 
anti-microbial agents, etc, may be used. The components can 
50 be added in any order that provides for the requisite binding. 
Incubations are performed at any suitable temperature, typi-
cally between 4° C. and 40° C. Incubation periods are 
selected for optimum activity, but may also be optimized to 
facilitate rapid high-throughput screening. Typically between 
55 0.1and1 hour will be sufficient. 
or disorders associated with ion channels, including, but not 
limited to diose associated with chloride channels (e.g., epi-
lepsy, renal tubular disorders, Bartter's syndrome, cystic 
fibrosis, osteopetrosis, Angleman or Prader-Willi, upregula-
tion of chloride channels in glioma cells, etc.), sodium chan-
nels (e.g., Hyperkalemic periodic paralysis, hypokalemic 
periodic paralysis, congenital Paramyotonia, Myotonia Flue- 60 
tuant, Myotonia Permanens, Acetazolamide-responsive myo-
tonia, malignant hyperthermia, nerve injury, epilepsy, various 
heart diseases, thyroid, endocrine, etc.). 
1. Methods for Identifying Agents that Modulate Scorpion 
Venom Polypeptide-Ion Channel Binding Activity 
One embodiment provides methods of identifying agents 
which modulate ABC transporter binding activity of ABC 
transporter ligands. The term "modulate" encompasses an 
increase or a decrease In the measured ABC transporter 
ligand-ABC transporter binding activity when compared to a 
suitable control. 
The terms "agent", "substance" and "compound" are used 
interchangeably herein. Candidate agents encompass numer- 65 
ous chemical classes, typically synthetic, semi-synthetic, or 
naturally-occurring inorganic or organic molecules. Candi-
The method generally comprises: 
a) contacting a substance to be tested, with a sample con-
taining a ABC transporter ligand such as GaTxl and an ABC 
transporter such as a chloride ion channel; and 
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b) measuring ABC transporter binding activity of the ABC 
transporter ligand in the presence of the substance. 
An increase or a decrease in ABC transporter binding activity 
in comparison to ABC transporter binding activity in a suit-
able control (e.g., a sample including ABC transporter ligand 
and an ABC transporter in the absence of the substance being 
tested) is an indication that the substance modulates a ABC 
transporter binding activity of the ABC transporter ligand. 
38 
tested, compared to a control to which no agent is added, is an 
indication that the agent modulates ABC transporter ligand 
expression. 
An agent being tested for its effect on ABC transporter 
ligand expression is assessed for any cytotoxic activity it may 
exhibit toward the cell used in the assay, using well-known 
assays, such as trypan blue dye exclusion, an MTT ([3-( 4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetraxolium bro-
mide]) assay, and the like. Agents that do not exhibit cytotoxic 
activity are considered candidate agents. 
The cells used in the assay are usually mammalian cells, 
including, but not limited to, rodent cells and human cells. 
The cells may be primary cell cultures. 
Scorpion venom toxin family polypeptide mRNA and/or 
polypeptide whose levels are being measured can be encoded 
by an endogenous scorpion venom toxin polynucleotide, or 
the scorpion venom toxin polynucleotide can be one that is 
comprised within a recombinant vector and introduced into 
the cell, i.e., the ABC transporter ligand mRNA and/or 
Methods for practicing such assays are known to those of 
skill in the art. (See, e.g., Mishina et al. (1985) Nature 313: 10 
364 369; and Noda, et al. Nature 322:836 828.) For example, 
ion channel activity may be measured by methods such as 
electrophysiology (two electrode voltage clamp or single 
electrode patch clamp), guanidinium ion flux assays, toxin-
15 
binding assays, and Fluorometric Imaging Plats Reader 
(FLIPR) assays. (See, e.g., Sullivan, et al. (1999) Methods 
Mo!. Biol. 114:125 133: Siegel and Isacoff (1997) Neuron 
19:1 20; and Lopatin, et al. (1998) Trends Pharmacol. Sci. 
19:395 398.) 
An "agent which modulates ABC transporter-ABC trans-
porter ligand binding activity", as used herein, describes any 
molecule, e.g. synthetic or natural organic or inorganic com-
pound, protein or pharmaceutical, with the capability of alter-
ing ABC transporter binding activity of a ABC transporter 25 
ligand, as described herein. Generally a plurality of assay 
mixtures are run in parallel with different agent concentra-
tions to obtain a differential response to the various concen-
trations. Typically, one of these concentrations serves as a 
negative control, i.e. at zero concentration or below the level 30 
of detection. Ion channel binding can be measured as 
described hereinabove. 
20 polypeptide can be encoded by an exogenous scorpion venom 
toxin polynucleotide. For example, a recombinant vector may 
comprise an isolated ABC transporter ligand transcriptional 
regulatory sequence, such as a promoter sequence, operably 
An agent which modulates ABC transporter binding activ-
linked to a reporter gene (e.g., ~-galactosidase, CAT, 
luciferase, or other gene that can be easily assayed for expres-
sion). In these embodiments, the method for identifying an 
agent that modulates a. level of ABC transporter ligand 
expression in a cell, comprises: combining a candidate agent 
to be tested with a cell comprising a nucleic acid which 
comprises a scorpion venom toxin gene transcriptional regu-
latory element operably linked to a reporter gene; and deter-
mining the effect of said agent on reporter gene expression. A 
recombinant vector may comprise an isolated ABC trans-
porter ligand transcriptional regulatory sequence, such as a 
promoter sequence, operably linked to sequences coding for 
a ABC transporter ligand; or the transcriptional control 
sequences can be operably linked to coding sequences for a 
scorpion venom toxin fusion protein comprising ABC trans-
porter ligand fused to a polypeptide which facilitates detec-
ity of a ABC transporter ligand increases or decreases the 
35 
activity at least about 10%, at least about 15%, at least about 
20%, at least about 25%, more preferably at least about 50%, 
more preferably at least about 100%, or 2-fold, more prefer-
ably at least about 5-fold, more preferably at least about 
10-fold or more when compared to a suitable control. 40 ti on. In these embodiments, the method comprises combining 
a candidate agent to be tested with a cell comprising a nucleic 
acid which comprises a scorpion venom toxin gene transcrip-
tional regulatory element operably linked to a ABC trans-
porter ligand-coding sequence; and determining the effect of 
2. Methods of Detecting Agents which Modulate a Level of 
Scorpion Venom Toxin Polypeptide mRNA and/or Polypep-
tide 
A wide variety of cell-based assays may be used for iden-
tifying agents which modulate levels of ABC transporter 
ligand polypeptide mRNA, using, for example, a manimalian 
cell transformed with a construct including a ABC trans-
porter-encoding cDNA such that the cDNA is overexpressed, 
or, alternatively, a construct including a ABC transporter gene 
promoter operably linked to a reporter gene. 
45 said agent on ABC transporter ligand expression, which 
determination can be carried out by measuring an amount of 
ABC transporter ligand mRNA, ABC transporter ligand, or 
scorpion venom toxin fusion polypeptide produced by the 
cell. 
50 
Accordingly, one embodiment provides a method for iden-
tifying an agent, particularly a biologically active agent, that 
modulates a level of ABC transporter ligand expression in a 
cell, the method including: combining a candidate agent to be 
tested with a cell comprising a nucleic acid which encodes a 55 
ABC transporter ligand; and determining the effect of said 
agent on ABC transporter ligand expression. A modulation, 
of ABC transporter ligand expression, levels includes 
increasing the level and decreasing the level of ABC trans-
porter ligand mRNA and/or scorpion venom toxin encoded 60 
by the scorpion venom toxin polynucleotide when compared 
to a control lacking the agent being tested. An increase or 
decrease of about 1.25-fold, usually at least about 1.5-fold, 
usually at least about 2-fold, usually at least about 5-fold, 
usually at least about 10-fold or more, in the level (i.e., an 65 
amount) of ABC transporter ligand mRNA and/or polypep-
tide following contacting the cell with a candidate agent being 
Cell-based assays generally comprise the steps of contact-
ing the cell with an agent to be tested, farming a test sample, 
and, after a suitable time, assessing the effect of the agent on 
ABC transporter ligand expression. A control sample com-
prises the same cell without the candidate agent added. ABC 
transporter ligand expression levels are measured in both die 
test sample and the control sample. A comparison is made 
between ABC transporter ligand expression level in the test 
sample and the control sample. ABC transporter ligand 
expression can be assessed using conventional assays. For 
example, when a mammalian cell line is transformed with a 
construct that results in expression of ABC transporter ligand, 
ABC transporter ligand mRNA levels can be detected and 
measured, as described above, or ABC transporter ligand 
levels can he detected and measured, as described above. A 
suitable period of time for contacting the agent with the cell 
can be determined empirically, and is generally a time suffi-
cient to allow entry of the agent into the cell and to allow the 
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agent to have a measurable effect on ABC transporter ligand 
mRNA and/or polypeptide levels. Generally, a suitable time is 
between 10 minutes and 24 hours, more typically about 18 
hours. Methods of measuring ABC transporter ligand mRNA 
levels are known in the art, several of which have been 
described above, and any of these methods can be used in the 
methods of the present invention to identify an agent which 
modulates ABC transporter ligand mRNA level in a cell, 
including, but not limited to, a PCR, such as a PCR employing 
detectably labeled oligonucleotide primers, and any of a vari-
ety of hybridization assays. Similarly, ABC transporter ligand 
levels can be measured using any standard method, several of 
which have been described herein, including, but not limited 
to, an immunoassay such as ELISA, for example an ELISA 
employing a detectably labeled antibody specific for a ABC 
transporter ligand. 
VI. Preparation of Antivenom and Antibodies 
Identification of potent components is an important first 
step in designing and obtaining effective antivenom. Antibod-
ies raised against the critical toxic components have the 
potential to block the toxic effects and reduce the pain asso-
ciated with the scorpion envenomation. Antibodies that spe-
cifically bind to scorpion venom toxin polypeptides, in par-
ticular to GaTxl are produced by; 1) immunization of non-
human animals with the isolated cells and production of 
hybridomas; and 2) identification of antibodies that specifi-
cally bind scorpion venom toxin polypeptides (e.g., by 
screening hybridoma supernatants with scorpion venom 
toxin). Each of these steps is described below. 
Antibodies specific to GaTxl are produced by immunizing 
a non-human mammal (e.g., murine, rodentia, lagomorpha, 
ovine, porcine, bovine, etc.) with isolated GaTxl. Immuni-
zation and hybridoma production with the scorpion venom 
toxin polypeptide can be accomplished according to conven-
tional methods well known in die art. The immunized animal 
is an immunocompetent, non-human mammalian host, 
including murine, rodentia, lagomorpha, ovine, porcine, 
bovine, etc, is immunized with scorpion venom toxin 
polypeptide isolated as described above. The choice of a 
particular host is primarily one of convenience. Immuniza-
tions are generally performed in accordance with conven-
tional techniques. 
Either monoclonal or polyclonal antibodies, preferably 
monoclonal antibodies (MAbs), are produced from the 
immunized animal. Polyclonal antisera may be harvested 
from serum in accordance with conventional methods after 
completion of the immunization schedule. For production of 
MAbs, lymphocytes are harvested from the appropriate lym-
phoid tissue, e.g. spleen, draining lymph node, etc., and fused 
with an appropriate fusion partner, usually a myeloma line, 
producing a hybridoma secreting a specific monoclonal anti-
body. Methods for hybridoma production are well known in 
the art (see, e.g., Antibodies, A Laboratory Manual, Harlow & 
Lane eds., (1988) Cold Spring Harbor Press). 
40 
tides in ELISA assays, etc.). Such screening is routine and 
with the guidance provided herein, within the skill of the 
ordinarily skilled artisan. 
Modified antibodies contemplated by the present invention 
include those produced using biochemical, chemical, or 
recombinant DNA techniques. For example, antibody frag-
ments, such as Fv, F(ab')2 and Fab may be prepared from the 
antibodies of the invention by cleavage of the intact protein, 
e.g., by protease or chemical cleavage. Alternatively, a trun-
10 cated gene is designed. For example, a chimeric gene encod-
ing a portion of the F(ab')2 fragment would include DNA 
sequences encoding the CH 1 domain and hinge region of the 
H chain, followed by a translational stop codon to yield the 
truncated molecule. Preferably, such antibody fragments 
15 retain antigen avidity and/or affinity that is substantially the 
same as the original antibody from which they are derived. 
The subject antibodies may also be produced as a single 
chain, instead of the normal multimeric structure. Single 
chain antibodies are described in Jost et al. (1994) J. Biol. 
20 Chem. 269:26267 73, and others. DMA sequences encoding 
the variable region of the heavy chain and the variable region 
of the light chain are ligated to a spacer encoding at least 
about four amino acids of small neutral amino acids, includ-
ing glycine and/or serine. The protein encoded by this fusion 
25 allows assembly of a functional variable region that retains 
the specificity and affinity of the original antibody. 
The antibodies may also be humanized. Methods of 
humanizing antibodies are well known in the art. The human-
ized antibody may be the product of an animal having trans-
30 genie human immunoglobulin (lg) constant region genes (see 
for example, WO 90/10077 and WO 90/04036). Alterna-
tively, the antibody of interest may be engineered by recom-
binant DNA techniques to substitute the CHv CH2 , CH3 , 
hinge domains, and/or the framework residues with the cor-
35 responding human sequence (see WO 92/02190). Humanized 
antibodies are of particular interest for in vivo use in humans. 
The antibodies may also be used to produce chimeric anti-
bodies. The use of lg cDNA for construction of chimeric lg 
genes is known in the art (Liu et al. (1.987) Proc. Natl. Acad. 
40 Sci. 84:3439; Liu eta!. (1987)1. Immunol, 139:3521).mRNA 
Is isolated from a hybridoma or other cell producing the 
antibody and used to produce cDNA. The cDNA of interest 
may be amplified by the polymerase chain reaction using 
specific primers (U.S. Pat. Nos. 4,683,195 and 4,683,202), 
45 Alternatively, a library is made and screened to isolate the 
sequence of interest. The DNA sequence encoding the vari-
able region, of the antibody is then fused to human constant 
region sequences. The sequences of human constant regions 
genes may be found in Kabat et al. (1.991) Sequences of 
50 Proteins oflmmunological Interest, N.I.H. publication no. 91 
3242. Human C region genes are readily available from 
known clones. The chimeric, humanized antibody is then 
expressed by conventional methods. 
Expression vectors for use in modification of the antibod-
55 ies of the invention are well known in the art and include 
The antibodies and MAbs can be modified in any of a 
variety of ways, with the proviso that the modified MAbs 60 
retain substantially specific binding to the original antigen 
(e.g., to the original scorpion venom toxin polypeptide). The 
ability of such modified antibodies to specifically and sensi-
tively bind their original antigen can be assessed in in vitro 
assays as described herein (e.g., to assess binding of the 65 
modified antibodies to scorpion venom toxin in cytospin 
preparations, to scorpion venom toxin cell-specific polypep-
plasmids, retroviruses, YACs, EBY derived episomes, and the 
like. For example, where the scorpion venom toxin polypep-
tide antibody is to be modified to provide a human antibody 
heavy and/or light chain constant region, a convenient vector 
is one that encodes a functionally complete human CH or CL 
lg sequence, with appropriate restriction sites engineered so 
that any VH or VL sequence can be easily inserted and 
expressed. In such vectors, splicing usually occurs between 
the splice donor site in the inserted J region and the splice 
acceptor site preceding the human C region, and also at the 
splice regions that occur within the human CH exons. Poly-
adenylation and transcription termination occur at native 
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chromosomal sites downstream of the coding regions. The 
resulting chimeric antibody may be joined to any strong pro-
moter, including retroviral LTRs, e.g. SV-40 early promoter, 
(Okayama et al. (1983) Mo!. Cell Biol. 3:280), Rous sarcoma 
virus LTR (Gorman et al. (1982) Proc. Natl. Acad. Sci. 
79:6777), and Moloney murine leukemia virus LTR (Gross-
chedl et al. (1985) Cell 41:885); native lg promoters, etc. 
VII. Kits 
42 
single channel patches. For all experiments except those 
depicted in FIG. 6 and FIG. 10, VM=-80 mV. The single 
channel record in FIG. 6 was performed at VM =-100 m V. For 
macropatch experiments, solutions containing 1 mM MgATP, 
no MgATP, fraction (or venom), or MgATP plus traction (or 
venom) were perfused onto the intracellular face of the chan-
nel using a last perfusion system (Warner instruments, model 
SF-77B), as previously described. All single channel record-
ings ofWT-CFTR were performed in the continuous presence 
The detection methods discussed above can be provided as 
part of a kit. Thus, one embodiment, provides kits for detect-
ing the presence and/or a level of ABC transporter ligand or 
ABC transporter ligand-encoding polynucleotides in a bio-
logical sample. Procedures using these kits can be performed 
10 of 1 mM MgATP and 50 U/mL PKA. Multi-channel patch 
experiments with Flag-cut-llR-CFTR in FIG. 7 were per-
formed in the continuous presence of 0.2 or 1 mM MgATP. 
Human ClC-1 and rabbit ClC-2 were expressed in oocytes 
and studied using two-electrode trade voltage clamp, as pre-
by clinical laboratories, experimental laboratories, medical 
practitioners, or private individuals. The kits for detecting a 
ABC transporter ligand include a moiety that specifically 
binds scorpion venom polypeptide, including, but not limited 
15 viously described. For experiments with ShB-IR, oocytes 
were injected with 0.06-1 ng cRNA. Leak currents were sub-
tracted using a P/4 protocol; corrected traces are shown. For 
all figures including electrophysiological recordings, the 
thick horizontal dashed line indicates die closed current level. 
20 Statistics to, ABC transporter ligand-specific antibody and an ion chan-
nel polypeptide. The kits for detecting a sABC transporter 
ligand-encoding polynucleotide include a moiety that specifi-
cally hybridizes to a ABC transporter ligand-encoding poly-
nucleotide. The kit may optionally provide additional com-
ponents that are useful in the procedure, including, but not 25 
limited to, buffers, developing reagents, labels, reacting sur-
faces, means for detections, control samples, standards, 
instructions, and interpretive information. 
Pharmaceutical kits for the treatment of scorpion stings, 
which include one or more containers containing a pharma- 30 
ceutical composition including a therapeutically effective 
amount of a GaTxl polypeptide compound or antibody to a 
GaTxl polypeptide. Such kits can further include, if desired, 
one or more of various conventional pharmaceutical kit com-
ponents, such as, for example, containers with one or more 35 
pharmaceutically acceptable carriers, additional containers, 
etc., as will be readily apparent to those skilled in the art. 
Printed instructions, either as inserts or as labels, indicating 
quantities of the components to be administered, guidelines 
for administration, and/or guidelines for mixing the compo- 40 
nents, can also be included in the kit. 
Results are reported as mean±S.E. for n observations. Sta-
tistical Significance was assessed using paired and unpaired 
Student's t-tests, Differences were considered statistically 
significant when p<0.05. 
Example 1 
Inhibition of CFTR by Scorpion Venom 
Venom from the scorpion L. quinquestriatus hebraeus was 
obtained from Latoxan (France) and processed as previously 
described. Briefly, venom was resuspended in recording solu-
tion, disrupted by a tissue grinder, and centrifuged in order to 
separate the mucous component. The supernatant was then 
passed through a 10 kDa MW cut-off spin filter to remove 
high molecular weight components, resulting in "Lqh-pf 
venom". Venom or traction concentrations are stated as 
equivalent to venom dry weight before processing. For toxin 
separation by chromatography, Lqh-pf venom was resus-
pended at a concentration of 5 mg/mL equivalent. 
A summary of the inhibitory activity of partially-fraction-
ated venom ("Lqh-pf venom") on CFTR channels in both 
macropatches and single-channel patches pulled from Xeno-
pus oocytes is shown in FIG. lb-d. Lqh-pf venom contains all 
components <10 kDa in size. Rapid application of0.1 mg/mL 
Lqh-pf venom (dilution equivalent to this concentration of 
unfractionated venom based upon venom dry weight) to 
closed wildtype (WT)-CFTR channels resulted in inhibition 
of macroscopic current by -25% at Vm=-80 mV, as previ-
The disclosure is further defined in the following 
Examples. It should be understood that these Examples, 
while indicating preferred embodiments, are given by way of 
illustration only. From the above discussion and these 45 
Examples, one skilled in the art can ascertain the essential 
characteristics of the various embodiments, and without 
departing from the spirit and scope thereof can make various 
changes and modifications to adapt to various usages and 
conditions. 50 ously described. Venom was applied to phosphorylated 
CFTR channels that had been allowed to close upon removal 
of cytosolic ATP. When ATP was returned to the bath, the 
resulting current density was reduced. Similar results were 
seen when Lqh-pfvenom was applied to Flag-cut-llR-CFTR 
EXAMPLES 
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55 channels (FIG. la right, FIG. lb right), which lack the regu-
latory R domain and therefore do not require PKA-mediated 
phosphorylation, suggesting that the decrease in current 
observed in WT-CFTR is due to venom-induced inhibition 
Adult female Xenopus were obtained from Xenopus One 
(Ann Arbor, Mich.). Methods for oocyte preparation have 
been previously described, cRNAs were prepared from high 
expression vectors encoding WT-CFTR (pGEMHE-WT) or 60 
Flag-cut-llR-CFTR (pGEMHE-Flag3-633 plus pGEMHE-
837-1480). Oocytes were injected with 5-25 ng cRNA for 
single channel experiments, or 25-100 ng cRNA for macro-
patch experiments. Methods for electrophysiological record-
ing of CFTR single channel and macropatch currents, and 65 
analysis, have been described previously. Briefly, all fractions 
were tested using either excised/inside-out macropatches or 
rather than channel rundown mediated by membrane-bound 
phosphatases. When the inhibitory activity was further char-
acterized at the single channel level, the active components) 
of venom inhibited channel activity in a complex manner. 
Application of Lqh-pf venom onto single WT-CFTR chan-
nels in excised patches resulted in a substantial decrease in 
channel open probability (P 
0
). As shown in FIG. le, venom 
application led to complete knockout of some channels for 
tens of seconds to minutes by binding to the channels in the 
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interburst closed state. Venom application also resulted in the 
introduction of toxin-induced intraburst blocked states in 
those channels that were able to open (FIG. ld); these events 
were previously shown to arise from venom binding during 
brief intra burst closings, leading to the prolongation of those 
intraburst closed states. These results suggest that Lqh-pf 
venom may contain two separate toxins that bind to CFTR 
during different phases of the gating cycle, or one toxin that 
Inhibits in two different ways. 
44 
affecting apparent burst duration. However, the venom-in-
duced intra burst closings that were apparent during inhibition 
by fraction C were notably absent (FIG. 3c). These findings 
suggest that at least two toxins active at CFTR are contained 
in Lqh-pfvenom and that the toxin responsible for inducing 
intraburst blocked states was not contained in fraction 
C-gf30-32. 
Example 2 
Separation of Active Components in Venom 
Fraction C-gf30-32 was then further separated by 
RP-HPLC (FIG. 4a). The chromatographic peak collected 
10 -15 minutes into the run, peak #6, was found to inhibit WT-
CFTR single channels (FIG. 4b). None of the other collected 
peaks had any inhibitory activity (data not shown). Single-
channel recordings ofWT-CFTR activity in the absence and 
15 
presence of peak #6 indicated that the fraction inhibited 
CFTR by inducing long-lived interburst closings (FIG. 4b). In 
contrast, die venom-induced intraburst closings were not 
present (FIG. 4c ). Peak #6-caused a 58.2±11.3% decrease in 
P 
0 
from 0.19±0.06 in control conditions to 0.06±0.004 (n=3) 
Lqh-pf venom was fractionated by means of reversed-
phase HPLC (RP-HPLC) (FIG. 2a). Components ofLqh-pf 
venom were separated based on hydrophobicity, using a 
Waters 1525 binary HPLC coupled to a Waters 2487 dual 
wavelength absorbance detector, with a Zorbax 300SB-C3 
silica colunm (4.6x250 mm, 5 µm, 300 A pore size), and a 
gradient of water and acetonitrile. Size exclusion-chromatog-
raphy used a 1.4 cmx80 cm chromatography column (Bio-
Rad) packed with Sephadex G50 Superfine (Sigma); toxins 
were eluted using a buffer containing 50 mM Tris-HCI and 
100 mM KC! (pH 7.5). Dextran, cytochrome C, and vitamin 25 
B were used as standards during column equilibration. All 
fractions collected via RP-HPLC or size exclusion chroma-
tography were dried under vacuum, then resuspended in the 
appropriate recording solution, and stored at -80° C. until 
use. For all chromatograms, the solid line indicates absor- 30 
bance at 220 nm. The dashed line in RP-HPLC chromato-
20 in presence of peak #6. From these results we concluded that 
peak #6 contained a peptide ligand which inhibited WT-
CFTR. 
Example 3 
Characterization of the Isolated Peptide Ligand 
grams indicates the elution gradient. 
Elution fractions were examined for activity against WT-
CFTR in excised inside-out macropatches (FIG. 2b, FIG. 2c). 
The fraction collected from 20-30 minutes (fraction "C") 
resulted in 23.7±3.4% (n=3) inhibition of macroscopic cur-
rent at a dilution equivalent to 0.1 mg/mL venom; however, 
fractions-collected at other times also had some effect. The 
wide ranging apparent inhibitory activity suggested by these 
data may be due to a small degree of dephosphorylation-
mediated rundown ofWT-CFTR. channels. Therefore, simi-
Initial characterization of the active peptide contained in 
peak #6 was accomplished by subjecting a small aliquot of the 
material to MAL DI-TO F analysis. A single peptide was iden-
tified with a molecular mass of3,674.6 Da (FIG. Sa), Addi-
tional, less/abundant peaks with similar mass were also iden-
tified that likely represent different oxidative states of the 
same toxin; a doubly charged species also was observed 
35 (m/z=l,838.8 Da). The peptide in peak #6 then was subjected 
to automated amino terminal sequencing following destruc-
tion of all putative disulfide bridges by reduction with DTT 
and alkylation of free cysteines by iodoacetamide. The reduc-
tion and alkylation of the native toxin resulted in an increase 
40 in molecular mass to 4,138.5 Da as determined by MALDI-
TOF, which is in agreement with the modification of eight 
cysteines; expected mass=4,138.6 Da (Table 2). lar experiments using Flag-cut-li.R-CFTR expressed in 
excised, inside-out macropatches were performed (FIG. 2b, 
FIG. 2c (right)). Fraction C resulted in 27.9±7.2% (n=4) 
inhibition of macroscopic Flag-cut-li.R-CFTR current; some 45 
activity spilled over into fraction D. 
To determine the mechanism of inhibition induced by 
venom fraction C, excised, inside-out patch recordings of 
single CFTR channels were studied in the absence and pres-
ence of fraction C (FIG., 2d). Exposure to fraction C resulted 50 
in a decrease in P 
0
, due to a decrease in channel opening rate 
associated with an apparent prolongation of the interburst 
closed duration. In addition, expanded displays of single open 
channel bursts indicated that application of fraction C also led 
to the introduction of intraburst closings (FIG. 2e). These 55 
results suggested that fraction C contains both of the activities 
previously described for venom. 
Sequential purification using gel-filtration .chromatogra-
phy (FIG. 3a) and RP-HPLC (FIG. 4a) resulted in the isola-
tion of a single peptide whose biological activity was suffi- 60 
cient to recapitulate the interburst inhibitory activity of crude 
venom. The size-exclusion fractions collected from 300-336 
minutes (fraction C-gf30-32) resulted In significant. Inhibi-
tion ofWT-CFTR current at the single-channel level. Record-
ings of WT-CFTR in the absence and presence of fraction 65 
C-gf30-32 suggested that the fraction inhibited CFTR by 
inducing long-lived interburst closings (FIG. 3b) without 
TABLE2 

















*Modified molecular mass represents the mass of the native toxin that has been reduced with 
DTT, and modified with iodoacetamide. 
The toxin isolated from venom, or the reduced/ carboxami-
domethy 1-modified toxin, was purified by microbore 
RP-HPLC (Applied Biosystems model 140A/785A system) 
on a Zorbax SB-C18 silica colunm (lx150 mm, 5 µm, 300 A 
pore size) equilibrated in 0.1 % aqueous TFA and eluted at 25° 
C. using a linear gradient of acetonitrile in 0.08% aqueous 
TFA. The toxin was eluted as a dominant peak absorbing at 
214 nm which was collected and further analyzed. 
US 8,106,013 B2 
45 
RP-HPLC fractions of either the native or reduced/car-
boxamidomethyl-modified intact toxin were sequenced. The 
peptides were loaded onto a Biobrene-coated and pre-cycled 
glass fiber filter disc and sequenced using a model cLC-
Procise sequencer/PTH Analyzer (Applied Biosystems) 5 
using the manufacturer's pulse-liquid Edman degradation 
chemistry cycles. To further confirm the sequence data 
obtained by N-terminal sequence analysis, an aliquot of the 
reduced/carboxamidomethyl-modified toxin was digested 
with Lys-C protease which is specific for Lys-Xxx peptide 10 
bonds. The digest was separated by RP-HPLC and the result-
ing three fractions were manually collected and subjected to 
Edman sequencing as above. The sequences of the three 
fragments corresponded to: (1) N-term.: 
15 
CGPCFTTDHQMEQK(residues 1-14 ofSEQIDNO:l); (2) 
Middle: CAECCGGIGK (residues lS-24 of SEQ ID NO:l); 
and (3) C-term.: CYGPQCLCNRamide (SEQ ID N0:38). 
The C-terminal fragment was further analyzed by ESI-MS/ 
MS, yielding a molecular ion of l,32S.S Da, which agrees 20 
with the calculated mass ofthis fragment based on sequence 
assuming a C-terminal amide. The ESI-MS/MS data also 
confirmed the presence of three carboxamidomethyl-Cys 
residues in this fragment. The primary sequence was deter-
mined to be: 1CGPCFTTDHQMEQKCAECCGGIGKCYG- 25 
PQCLCNR34 (SEQ ID NO:l), including C-terminal amida-
tion as the only post-translational modification other than 
formation of disulfide bridges. 
Peptide monoisotopic masses (Table 2) were obtained by 
MALDI-TOF MS analysis using the Applied Biosystems 30 
model 4700 Proteomics Analyzer (MALDI-TOF/TOF) sys-
tem operated in the reflector mode. The calculated mass of the 
isolated toxin based upon primary sequence and assuming 
post-translational C-terminal amidation was in close agree-
ment with the mass determined by MS; these results suggest 35 
that the toxin does not include bound metal ions. To confirm 
46 
FIG. Sc shows the NMR structure ofC!Tx and the homol-
ogy model ofGaTxl, in three orientations. The two structures 
are quite similar in shape and secondary structure, although 
GaTxl has three regions of anti-parallel ~-strand compared to 
two in C!Tx; the extra strand is at the immediate N-terminus. 
The ISA toxin structure (not shown) includes three ~-strands 
and a longer a-helix compared to C!Tx. GaTxl is also some-
what more compact than C!Tx, partly due to the insertion of 
two amino acids C-terminal to the a-helix In C!Tx, and due to 
the lack of defined secondary structure in the first loop Of 
C!Tx, resulting in a bulge of relatively disordered sequence at 
the N-terminal end of the a-helix in C!Tx. FIG. Sd identifies 
the borders of regions of predicted secondary structure for 
GaTxl, and compares the GaTxl sequence with that of C!Tx 
and charybdotoxin (ChTx). While the most striking primary 
structure differences between short-chain insectotoxins (in-
cluding all three of these) and the longer toxins that inhibit 
Na+ channels and Ca2+ channels 10 are the lengths ofloops 2 
and 3, the major differences between GaTxl (which inhibits 
CFTR) and C!Tx (which does not) are in the a-helix. 
Example 4 
Kinetics oflnhibition ofCFTR by GaTxl 
FIG. 6 shows data from a single-channel recording ofWT-
CFTR in the absence of toxin (upper and lower traces) and in 
the presence of 60 nM GaTxl (middle trace), indicating 
reversible inhibition. Consistent with the data shown in FI GS. 
1-4, exposure of single CFTR channels to GaTxl in aninside-
out patch led to the introduction oflong closed/blocked states 
without affecting the duration of the open states. Toxin-in-
duced closed durations are very long; the mean toxin-Induced 
closed duration in this experiment was >S seconds. However, 
evident in the dwell-time distribution (FIG. 6e) are toxin-
induced closed states that lasted nearly a minute. Similarly 
long toxin- or venom-induced closed durations are evident in 
FIGS. 1-4. Hence, GaTxl interacts with CFTR -1.000-fold 
longer than most known blockers. This intimate interaction 
the primary sequence, an aliquot of the reduced/carboxami-
domethyl-modified toxin was digested with Lys-C protease 
and analyzed by Edman degradation and ESI-MS/MS, result-
ing in the same primary sequence data. The same toxin has 
been purified from three different batches of scorpion venom. 
40 means that GaTxl will be a very informative probe of CFTR 
structure. 
Example S 
Synthetic GaTxl Selectively Inhibits CFTR 
To confirm that the inhibitory activity in venom could be 
ascribed to the sequenced toxin, and did not arise from a 
contaminant, GaTxl was prepared by solid-phase chemistry. 
The general methods for peptide synthesis and purification, 
and disulfide bond formation, have been described previ-
ously. In brief, linear peptides were produced by solid phase 
synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) chem-
istry. Coupling ofFmoc amino acids was performed using the 
Comparisons of the primary sequence with those of other 
known or putative peptide ligands suggested that the isolated 
toxin, which is named GaTxl, is novel, with C!Tx-d as its 
closest relative (FIG. Sb). C!Tx-d is not known to inhibit any 45 
ion channel; indeed, the sequences of C!Tx-b, -c, and-dare 
speculative, being predicted from the sequences of cDNAs 
cloned from scorpion venom gland. GaTxl bears 7S% 
sequence identity to C!Tx, but is smaller by -400 Da. The 
calculated pl values for GaTxl and C!Tx are 6.71 and 8.13, 50 
respectively. The primary sequence of GaTxl, the molecular 
mass, and the inferred presence of four disulfide bridges 
between conserved cysteines place this toxin in the family of 
short-chain insectotoxins active at K+ channels and putative 
toxins active at c1- channels. 
A homology model of GaTxl was created based on the 
known NMR structures of C!Tx and insectotoxin SA (ISA) 
(sequences 10 and 12 in FIG. Sb). The homology model of 
GaTxl was created using Modeller 8.2, with the NMR struc-
tures of chlorotoxin and insectotoxin ISA providing template 60 
structures. The GaTxl homology model was then subjected 
55 HBTU/HOBT/DIPEA method on an Applied Biosystems 
431A synthesizer. The purified linear peptide was subjected 
to oxidative cyclization under equilibrating conditions in 
order to promote formation of the most stable disulfide 
to a S ps, 2SOO step energy minimization in a solvated envi-
ronment using NAMDv2 with the charmm22 force field. 
Disulfide bridges were patched in order to ensure that disul-
fide bonds remained intact during energy minimization. All 65 
graphics were rendered from VMD 1.8.4 software in combi-
nation with POV-Ray 3.6. 
bridges, with the reaction being monitored by analytical 
HPLC Cyclized peptide was isolated from the acidified reac-
tion mixture by reversed phase extraction, was purified by 
HPLC, and was characterized by MALDI-MS for molecular 
weight determination (FIG. 8) and by analytical HPLC (FIG. 
9) for comparison with the native toxin. 
After purification by HPLC, MS analysis indicated that the 
synthetic linear peptide has a mass in agreement with the 
theoretical mass forthe linear form (i.e., all di sulfides reduced 
US 8,106,013 B2 
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to sulfhydryls) of the native toxin (Table 2). The linear peptide 
was subjected to oxidative cyclization and refolding was per-
formed over three days under equilibrating conditions, in 
order to promote the formation of the most stable disulfide 
bridges. The mass of the folded synthetic peptide differed 
from, the observed mass of the native toxin isolated from 
venom by only 0.5 a.m.u. (FIG. 8); in RP-HPLC experiments, 
folded synthetic toxin co-eluted with the native toxin (FIG. 
9). 
Multichannel patch recordings from oocytes expressing 10 
Flag-cut-llR-CFTR were used to test for activity of synthetic 
GaTxl (FIG. 7a), taking advantage of the insensitivity of this 
CFTR variant to dephosphorylation-mediated rundown; 
Flag-cut-llR-CFTR is inhibited by venom to a similar degree 
as WT-CFTR (FIG. lb). Because GaTxl binds to channels in 15 
the closed state, intracellular solution containing only 0.2 
mM ATP was used, which leads to reduced open probability, 
thus increasing the likelihood of a toxin binding event. FIG. 
7b shows a dose-response curve for inhibition of Flag-cut-
llR-CFTR under these conditions. The data were fit with a 20 
3-parameter Hill function providing a Kn of24.9 nM and Hill 
coefficient of 1.95. Maximum inhibition over this concentra-
tion range, and in the continual presence of 0.2 mMATP, was 
71.5%. Previous experiments indicated that venom was more 
effective when applied to CFTR channels in the absence of 25 
ATP, leading to strong state-dependence of action. The appar-
ent potency for toxin-mediated inhibition of channel activity 
would be very protocol dependent; under conditions that 
increase P 
0
, the apparent magnitude of inhibition should be 
reduced. As shown in FIG. 7b, 50 nM GaTxl led to 30 
56.2±5.0% inhibition ofFlag-cut-llR-CFTR in the presence 
of0.2 mMATP, but only 20.4±0.5% inhibition in the presence 
of 1 mM ATP (p=0.001 ). The observation that toxin efficacy 
depends upon [ATP], combined with a Hill coefficient near 2, 
suggests that GaTxl may inhibit CFTR by interacting with 35 
the nucleotide-binding domains (NBDs). 
To verify the specificity ofGaTxl-mediated inhibition, the 
ability of the toxin to inhibit ClC-1 and ClC-2 channels 
expressed in oocytes was tested and studied using two-elec-
trode voltage clamp (FIG. lOa, FIG. lOb). Our previous work 40 
showed that fraction C or Lqh-pf venom did not inhibit oocyte 
endogenous Ca2+ -activated c1- channels, or ClC-0 or ClC-1 
voltage-gated Cl- channels; Lqh-pf venom does contain a 
separate toxin that inhibits ClC-2 channels, although this is 
<160> NUMBER OF SEQ ID NOS, 39 
<210> SEQ ID NO 1 
<211> LENGTH, 34 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 1 
48 
not a component of fraction C. For ClC-1, fractional current 
remaining at +60 and -0.120 mV in the presence of 60 nM 
synthetic GaTxl was 1.02±0.03 and 1.02±0.02, respectively. 
For ClC-2, fractional time-dependent current remaining at the 
end of a long pulse to -160 m V was 0.98±0.03 in the presence 
of 60 nM GaTxl. These data suggest that the GaTxl toxin 
does not inhibit either ClC-1 or ClC-2 voltage-gated chloride 
channels at a concentration at which it effectively inhibits 
CFTR. GaTxl bears distant homology to the very well-
known charybdotoxin (ChTx) which inhibits a wide variety 
of voltage-gated and Ca2+-activated K+ channels (FIG. Sd). 
Whether GaTxl crosses over from c1- channel to K+ channel 
targets was determined by assaying for effects on K+ channel 
currents mediated by Shaker Kvl.1 channels expressed in 
oocytes. For these experiments, the ShB variant was used 
with inactivation-removed (ShB-IR). As shown in FIG. lOc, 
GaTxl had no effect on ShB-IR K+ currents at a toxin con-
centration that effectively inhibits CFTR. As a positive con-
trol, FIG. lOc shows 15% inhibitionofShB-IR currents by 24 
nM recombinant ChTx. This amount of inhibition is consis-
tent with the reported K, for ChTx-mediated inhibition of 
Shaker channels of -200 nM . 
Previous studies indicated that a toxin or toxins contained 
in Lqh venom preferentially inhibits CFTR activity in a state 
dependent manner by binding to channels when they are in 
either the interburst or intra burst closed states. Initial charac-
terization of the inhibitory activity of GaTxl suggested that 
the toxin only interacts with CFTR when the channel is in the 
interburst closed-state, usually thought to represent disrup-
tion of the NBD1-NBD2 dimer. These results suggest a sub-
stantial change in conformation of the cytoplasmic domains 
of CFTR during ATP-dependent channel gating. In patches 
bearing a few CFTR channels, application of GaTxl or 
venom resulted in channels that were locked in the interburst 
closed state for many tens of seconds to minutes (at least 1, 2, 
or 3 minutes) or causing them to appear to drop out of the 
record. However, the intraburst inhibition evident in experi-
ments with either Lqh-pf venom or venom fraction C was not 
present when GaTxl was used in isolation. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
Cys Gly Pro Cys Phe Thr Thr Asp His Gln Met Glu Gln Lys Cys Ala 
1 5 10 15 
Glu Cys Cys Gly Gly Ile Gly Lys Cys Tyr Gly Pro Gln Cys Leu Cys 
20 25 30 
Asn Arg 
<210> SEQ ID NO 2 
<211> LENGTH, 102 
<212> TYPE, DNA 
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-continued 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 2 
tgtggacctt gctttacaac ggatcatcaa atggaacaga agtgtgcaga atgttgcgga 60 
ggcattggaa aatgctatgg tccacaatgt ttgtgtaata gg 102 
<210> SEQ ID NO 3 
<211> LENGTH, 11 
<212> TYPE, PRT 
<213> ORGANISM: Human immunodeficiency virus 
<400> SEQUENCE, 3 
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 10 
<210> SEQ ID NO 4 
<211> LENGTH, 9 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic protein transduction domain 
<400> SEQUENCE, 4 
Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1 5 
<210> SEQ ID NO 5 
<211> LENGTH, 15 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequenec 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 5 
ggaggcauug gaaaa 
<210> SEQ ID NO 6 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 
uggaccuugc uuua 
<210> SEQ ID NO 7 
<211> LENGTH, 15 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 7 
ggaccuugcu uuaca 
<210> SEQ ID NO 8 
<211> LENGTH, 15 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 







<210> SEQ ID NO 9 
<211> LENGTH, 14 
<212> TYPE, RNA 
51 
<213> ORGANISM: artificial sequensce 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 9 
cagaagugug caga 
<210> SEQ ID NO 10 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 10 
caauguuugu guaa 
<210> SEQ ID NO 11 
<211> LENGTH, 15 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 11 
caauguuugu guaau 
<210> SEQ ID NO 12 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 12 
acaacggauc auca 
<210> SEQ ID NO 13 
<211> LENGTH, 15 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 13 
gaacagaagu gugca 
<210> SEQ ID NO 14 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 14 
gaagugugca gaau 
<210> SEQ ID NO 15 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 









<400> SEQUENCE, 15 
ggaggcauug gaaa 
<210> SEQ ID NO 16 
<211> LENGTH, 15 
<212> TYPE, RNA 
53 
<213> ORGANISM: artificial seqence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 16 
ugcuaugguc cacaa 
<210> SEQ ID NO 17 
<211> LENGTH, 14 
<212> TYPE, RNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic siRNA 
<400> SEQUENCE, 17 
aacggaucau caaa 
<210> SEQ ID NO 18 
<211> LENGTH, 19 
<212> TYPE, PRT 
<213> ORGANISM, Drosophila melanogaster 
<400> SEQUENCE, 18 
US 8,106,013 B2 
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Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp 
1 5 10 15 
Lys Lys Cys 
<210> SEQ ID NO 19 
<211> LENGTH, 14 
<212> TYPE, PRT 
<213> ORGANISM, Drosophila melanogaster 
<400> SEQUENCE, 19 
Ser Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Cys 
1 5 10 
<210> SEQ ID NO 20 
<211> LENGTH, 34 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 20 
Cys Gly Pro Cys Phe Thr Thr Asp His Gln Thr Glu Gln Lys Cys Ala 
1 5 10 15 
Glu Cys Cys Gly Gly Ile Gly Lys Cys Tyr Gly Pro Gln Cys Leu Cys 
20 25 30 
Asn Arg 
<210> SEQ ID NO 21 
<211> LENGTH, 33 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 21 
Cys Gly Pro Cys Phe Thr Thr Asp His Gln Thr Glu Gln Lys Cys Ala 
1 5 10 15 
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Arg 
<210> SEQ ID NO 22 
<211> LENGTH, 33 




<213> ORGANISM: Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 22 
Cys Gly Pro Cys Phe Thr Thr Asp Arg Gln Met Glu Gln Lys Cys Ala 
1 5 10 15 
Glu Cys Cys Gly Gly Ile Gly Lys Cys Tyr Gly Pro Gln Cys Leu Cys 
20 25 30 
Arg 
<210> SEQ ID NO 23 
<211> LENGTH, 35 
<212> TYPE, PRT 
<213> ORGANISM: Mesobuthus martensii 
<400> SEQUENCE, 23 
Cys Gly Pro Cys Phe Thr Thr Asp Ala Asn Met Ala Arg Lys Cys Arg 
1 5 10 15 
Glu Cys Cys Gly Gly Ile Gly Lys Cys Phe Gly Pro Gln Cys Leu Cys 
20 25 30 
Asn Arg Ile 
35 
<210> SEQ ID NO 24 
<211> LENGTH, 35 
<212> TYPE, PRT 
<213> ORGANISM: Mesobuthus martensii 
<400> SEQUENCE, 
Cys Gly Pro Cys 
1 
Glu Cys Cys 








<210> SEQ ID NO 25 
<211> LENGTH, 35 
<212> TYPE, PRT 
Thr Thr Asp Ala 
Asn Gly Lys Cys 
25 
Asn Met Ala Arg Lys 
10 
Phe Gly Pro Gln Cys 
30 
<213> ORGANISM: Androctonus mauretanicus mauretanicus 
<400> SEQUENCE, 
Cys Gly Pro Cys 
1 
Thr Cys Cys 








<210> SEQ ID NO 26 
<211> LENGTH, 36 
<212> TYPE, PRT 
Thr Thr Asp Pro 
Arg Gly Lys Cys 
25 
<213> ORGANISM, Buthus sindicus 
<400> SEQUENCE, 26 
Tyr Thr Glu Ser Lys 
10 








Cys Gly Pro Cys Phe Thr Lys Asp Pro Glu Thr Glu Lys Lys Cys Ala 
56 
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-continued 
1 5 10 15 
Thr Cys Cys Gly Gly Ile Gly Arg Cys Phe Gly Pro Gln Cys Leu Cys 
20 25 30 
Asn Arg Gly Tyr 
35 
<210> SEQ ID NO 27 
<211> LENGTH, 35 
<212> TYPE, PRT 
<213> ORGANISM, Buthus eupeus 
<400> SEQUENCE, 27 
Met Cys Met Pro Cys Phe Thr Thr Asp His Asn Met Ala Lys Lys Cys 
1 5 10 15 
Arg Asp Cys Cys Gly Gly Asn Gly Lys Cys Phe Gly Pro Gln Cys Leu 
20 25 30 
Cys Asn Arg 
35 
<210> SEQ ID NO 28 
<211> LENGTH, 36 
<212> TYPE, PRT 
<213> ORGANISM, Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 28 
Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys 
1 5 10 15 
Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln 
20 25 30 
Cys Leu Cys Arg 
35 
<210> SEQ ID NO 29 
<211> LENGTH, 36 
<212> TYPE, PRT 
<213> ORGANISM, Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 29 
Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys 
1 5 10 15 
Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln 
20 25 30 
Cys Leu Cys Arg 
35 
<210> SEQ ID NO 30 
<211> LENGTH, 35 
<212> TYPE, PRT 
<213> ORGANISM, Buthus sindicus 
<400> SEQUENCE, 30 
Arg Cys Lys Pro Cys Phe Thr Thr Asp Pro Gln Met Ser Lys Lys Cys 
1 5 10 15 
Ala Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 
20 25 30 
Cys Leu Cys 
35 
<210> SEQ ID NO 31 
<211> LENGTH, 35 
<212> TYPE, PRT 
US 8,106,013 B2 
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-continued 
<213> ORGANISM, Buthus eupeus 
<400> SEQUENCE, 31 
Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Lys Lys Cys 
1 5 10 15 
Arg Asp Cys Cys Gly Gly Asn Gly Lys Cys Phe Gly Pro Gln Cys Leu 
20 25 30 
Cys Asn Arg 
35 
<210> SEQ ID NO 32 
<211> LENGTH, 35 
<212> TYPE, PRT 
<213> ORGANISM, Buthus eupeus 
<400> SEQUENCE, 32 
Met Cys Met Pro Cys Phe Thr Thr Asp Pro Asn Met Ala Asn Lys Cys 
1 5 10 15 
Arg Asp Cys Cys Gly Gly Gly Lys Lys Cys Phe Gly Pro Gln Cys Leu 
20 25 30 
Cys Asn Arg 
35 
<210> SEQ ID NO 33 
<211> LENGTH, 38 
<212> TYPE, PRT 
<213> ORGANISM, Leiurus quinquestriatus hebraeus 
<400> SEQUENCE, 33 
Arg Cys Ser Pro Cys Phe Thr Thr Asp Gln Gln Met Thr Lys Lys Cys 
1 5 10 15 
Tyr Asp Cys Cys Gly Gly Lys Gly Lys Gly Lys Cys Tyr Gly Pro Gln 
20 25 30 
Cys Ile Cys Ala Pro Tyr 
35 
<210> SEQ ID NO 34 
<211> LENGTH, 36 
<212> TYPE, PRT 
<213> ORGANISM, Buthus eupeus 
<400> SEQUENCE, 34 
Met Cys Met Pro Cys Phe Thr Thr Arg Pro Asp Met Ala Gln Gln Cys 
1 5 10 15 
Arg Ala Cys Cys Lys Gly Arg Gly Lys Cys Phe Gly Pro Gln Cys Leu 
20 25 30 
Cys Gly Tyr Asp 
35 
<210> SEQ ID NO 35 
<211> LENGTH, 37 
<212> TYPE, PRT 
<213> ORGANISM, Buthus tamulus 
<400> SEQUENCE, 35 
Arg Cys Gly Pro Cys Phe Thr Thr Asp Pro Gln Thr Gln Ala Lys Cys 
1 5 10 15 
Ser Glu Cys Cys Gly Arg Lys Gly Gly Val Cys Lys Gly Pro Gln Cys 
20 25 30 
US 8,106,013 B2 
Ile Cys Gly Ile Gln 
35 
<210> SEQ ID NO 36 
<211> LENGTH, 36 
<212> TYPE, PRT 
61 
<213> ORGANISM, Buthus eupeus 
<400> SEQUENCE, 36 
-continued 
Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Thr Ala Arg Arg Cys 
1 5 10 15 
Arg Asp Cys Cys Gly Gly Arg Gly Arg Lys Cys Phe Gly Gln Cys Leu 
20 25 30 
Cys Gly Tyr Asp 
35 
<210> SEQ ID NO 37 
<211> LENGTH, 36 
<212> TYPE, PRT 
<213> ORGANISM, Mesobuthus tamulus 
<400> SEQUENCE, 37 
Arg Cys Pro Pro Cys Phe Thr Thr Asn Pro Asn Met Glu Ala 
1 
Arg Lys Cys Cys 
20 




<210> SEQ ID NO 38 
<211> LENGTH, 10 
<212> TYPE, PRT 
Gly Arg Gly Tyr 
25 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
10 
Cys Ala Ser Tyr 
<223> OTHER INFORMATION, synthetic peptide 
<220> FEATURE, 
<221> NAME/KEY, MISC_FEATURE 
<222> LOCATION, (10) .. (10) 
<223> OTHER INFORMATION, amidated 
<400> SEQUENCE, 38 
Cys Tyr Gly Pro Gln Cys Leu Cys Asn Arg 
1 5 10 
<210> SEQ ID NO 39 
<211> LENGTH, 37 
<212> TYPE, PRT 
<213> ORGANISM: Leiurus quinquestriatus hebraeus 






Gln Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val 
1 5 10 15 
Cys Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys 
20 25 30 
Cys Arg Cys Tyr Ser 
35 
62 
US 8,106,013 B2 
63 
We claim: 
1. A single polypeptide isolated from scorpionL. quinques-
triatus hebraeus venom comprising the amino acid sequence 
ofSEQIDNO:l. 
2. The polypeptide of claim 1, wherein the polypeptide 
binds cystic fibrosis transmembrane conductance regulator. 
3. The polypeptide of claim 2, wherein the polypeptide 
interacts with cystic fibrosis transmembrane conductance 
regulator in the interburst state. 
64 
8. An ex vivo method of reducing chloride transport 
through a cystic fibrosis transmembrane conductance regula-
tor ( CFTR) channel comprising contacting the CFTR channel 
with the polypeptide of claim 1 or 5. 
9. A method for treating a disorder or symptom of a disor-
der related to increased cystic fibrosis transmembrane con-
ductance regulator (CFTR) activity comprising: 
4. The polypeptide of claim 3, wherein binding of the 10 
polypeptide to the cystic fibrosis transmembrane conduc-
tance regulator locks closed the cystic fibrosis transmem-
brane conductance regulator. 
administering a therapeutically effective amount of the 
polypeptide according to claim 1 or 5, wherein the dis-
order is diarrhea-predominant inflammatory bowel syn-
drome, autosomal dominant polycystic kidney disease 
(ADPKD), or secretory diarrhea. 
10. An in vivo method of reducing chloride transport 
through cystic fibrosis transmembrane conductance regulator 5. An isolated synthetic or recombinant polypeptide com-
prising the amino acid sequence of SEQ ID NO: 1. 
6. A pharmaceutical composition comprising an effective 
amount of the polypeptide according to claim 1or5 to reduce 
chloride transport through cystic fibrosis transmembrane 
conductance regulator and a pharmaceutically acceptable 
diluent, preservative, solubilizer, emulsifier, adjuvant or ear-
ner. 
7. A composition comprising the polypeptide of claim 1 or 
5. 
15 (CFTR) in a subject having a disorder related to increased 
CFTR activity, comprising administering to the polypeptide 
of claim 1 or 5 such that CFTR is contacted with the polypep-
tide, wherein the disorder is diarrhea-predominant inflamma-
tory bowel syndrome, autosomal dominant polycystic kidney 
20 disease (ADPKD), or secretory diarrhea. 
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